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ABSTRACT
The main treatment option for castration-resistant prostate cancer (CRPC) is androgen
receptor pathway inhibition (ARPI). Selection pressure and lineage plasticity of ARPI
could lead to neuroendocrine (NE) differentiation of prostate cancer (PC), promoting the
more prevalent subtype of CRPC which is termed treatment-induced neuroendocrine
prostate cancer (NEPC) or t-NEPC. Treatment options for NEPC are limited to platinumand cisplatin-based combinations and median survival of NEPC patients is much lower
than patients with CRPC. Early identification of NEPC and novel targeting options could
be valuable. The transmembrane protein prostate-specific membrane antigen (PSMA) is an
appealing target for molecular imaging and therapy of PC since it is over-expressed in a
majority of PC tumors and metastatic lesions. Targeting PSMA is feasible by a wide variety
of radio-ligands. The PSMA ligands can also be labeled with therapeutic radionuclides
which can irradiate PSMA-expressing cells. Despite the positive implications of PSMA for
many forms of advanced AdPC there are clinical reports supporting that PSMA-targeted
imaging is not able to delineate NEPC tumors. Previous clinical reports indicate that PCs
with a phenotype related to NE tumors can be more responsive to imaging by
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Fluorodeoxyglucose (FDG) rather than PSMA-targeting radioligands.
In this work, we evaluated the association between NE gene signature and FDG
uptake-associated genes including glucose transporters (GLUTs) and hexokinases, with the
goal of providing a genomic signature to explain the reported FDG-avidity of PSMAsuppressed tumors. We use data mining approaches, cell lines and patient-derived
xenograft (PDX) models to study the levels of 14 members of the SLC2A family (encoding
GLUT proteins), 4 members of the hexokinase family (genes: HK1 to 3 and GCK) and
vii

PSMA (FOLH1 gene) following AR-inhibition and in correlation with NE hallmarks. Also,
we characterize a NE-like PC (NELPC) subset among a cohort of primary and metastatic
PC samples with no NE histopathology. We measured glucose uptake in a NE-induced in
vitro model and a zebrafish model by non-radioactive imaging of glucose uptake using
fluorescent glucose bioprobe, GB2-Cy3.
This work demonstrates that a NE gene signature associates with differential
expression of genes encoding GLUT and hexokinase proteins. In NELPC, elevated
expression of GCK (encoding glucokinase protein) and decreased expression of SLC2A12
correlated with earlier biochemical recurrence. In tumors treated with AR-inhibitors,
enhanced expression of GCK and low expression of SLC2A12 correlated with NE
histopathology and PSMA gene suppression. GLUT12-suppression and enhanced
expression of glucokinase was observed in NE-induced PC cell lines and PDX models. A
higher glucose uptake was confirmed in low-PSMA tumors using a GB2-Cy3 probe in a
zebrafish model.
In summary, a NE gene signature in NEPC and NELPC associates with a distinct
transcriptional profile of GLUTs and HKs. In transcriptomic level, PSMA-suppression
correlates with GLUT12-supression and glucokinase-upregulation. Alteration of FDG
uptake-associated genes correlated positively with higher glucose uptake in AR and
PSMA-suppressed tumors. Zebrafish xenograft tumor models are an accurate and efficient
pre-clinical method for monitoring non-radioactive glucose uptake.
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CHAPTER 1 : GENERAL INTRODUCTION
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1.1

PROSTATE MOLECULAR BIOLOGY

1.1.1

Androgen Synthesis in Leydig Cells

Hormones that contribute in male traits and reproductive activity are referred as androgens.
Testosterone is formed mostly by the testicles and dihydrotestosterone (DHT) as a
metabolite of testosterone mainly regulates the prostate (Wein, Kavoussi et al., 2011).
Testosterone, as principle androgen, regulates key steps of male reproductive system
development and is indispensable for homeostasis of a variety of tissues including prostate
gland (Wang, Chen et al., 2017). Figure 1-1A shows gonadotropin-releasing hormone
(GnRH) which is produced by the hypothalamus and regulates secretion of luteinizing
hormone (LH). The anterior pituitary gland releases gonadotropic hormone LH into the
blood. LH binds to its receptors on Leydig cells in testis, stimulating testosterone synthesis
by increasing levels of intracellular level of cyclic adenosine monophosphate (cAMP)
which stimulates the transport of cholesterol to the mitochondria to be converted to
pregnenolone. Pregnenolone is converted into testosterone in the smooth endoplasmic
reticulum and then testosterone is released to the blood.

1.1.2

Androgen Signaling in Prostate Gland

The prostate is an exocrine gland of the male reproductive system in most mammals (Josef
Marx & Karenberg, 2009). This walnut-sized gland surrounds the urethra under the bladder
and can be sensed during a rectal exam as a first method of detecting potential prostate
problems (Fowke, Motley et al., 2007). Figure 1-1B illustrates the anatomic location of the
prostate and demonstrates that the gland contains epithelial tissues surrounded by a
fibromuscular stroma. The function of the prostate is to secrete a slightly alkaline fluid that
constitutes about 30% of the volume of semen together with spermatozoa and seminal
2

vesicle fluid. The alkalinity of semen helps to neutralize the acidity of the vaginal tract
thereby extending the lifetime of sperm (Huggins, Scott et al., 1942). At a cellular level
AR-positive secretory epithelial cells are situated on a basal lamina (Figure 1-1C). Basal
cells and rare neuroendocrine (NE) cells are in the epithelial compartment. The stromal
cells surrounding the epithelial layer consists of a variety of cell types such as smooth
muscle cells, fibroblasts cells and blood vessels (Barron & Rowley, 2012). NE-like cells
have been suggested to comprise another possible subset of prostate cells with partial NEcharacters (Bakht, Derecichei et al., 2019a, Bakht, Lovnicki et al., 2019c, Spratt, Alshalalfa
et al., 2019).
The AR protein is encoded by the AR gene and acts as a nuclear receptor which is
activated by binding testosterone and DHT. When AR is unoccupied by androgens it can
be associate as a complex with heat shock proteins (HSP) to prevent AR degradation (Smith
& Toft, 2008). Figure 1-1C displays binding of DHT to the AR leading to dissociation from
HSP and nuclear translocation of the AR. As a DNA-binding transcription factor AR
regulates gene expression of a variety of proteins (Dai, Heemers et al., 2017).
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Figure 1-1 Leydig cell steroidogenesis and PSMA expression in prostate gland.
(A) A schematic of the testosterone production in Leydig cell of testis. (B) A schematic of cellular

structure of a prostate gland. (C) A summary of androgen activated AR signaling, PSA
expression and secretion. (D) A representative PSMA IHC staining of normal prostate
tissue. Image available from version 18, Human Protein Atlas (HPA)
(https://www.proteinatlas.org/ENSG00000086205-FOLH1). (E) A schematic of the
PSMA structure and enzymatic function suggested by (Kaittanis, Andreou et al., 2018).
PSMA has intracellular (i), transmembrane (ii) and extracellular (ii-iv) portions. T,
testosterone; DHT, dihydrotestosterone; HSP, heat shock protein; ARE, androgen response
element.
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1.1.3

Prostate Specific Antigen Biology

Kallikreins are a subset of serine proteases and prostate specific antigen (PSA) is a
glycoprotein in this subset. Kallikrein related peptidase 3 (KLK3) gene is positively
regulated by AR protein and codes PSA protein (Salman, Schoots et al., 2015). Figure 1-1C
demonstrates PSA regulation and its secretion. The majority of secreted PSA goes into the
seminal fluid to cleave the proteins responsible for seminal clot formation. PSA enzymatic
activity leads to declining seminal viscosity and helps motility of spermatozoa (Salman et
al., 2015). Figure 1-1B illustrates PSA should be restricted to the prostate gland due to
well-fitting and arranged prostate gland architecture in a normal prostate tissue. However,
a very low level of the secreted PSA in a gland could be transported in the circulation
(Salman et al., 2015).

1.1.4

PSMA biology

PSMA is transmembrane glycoprotein with folate hydrolase and carboxypeptidase
capabilities that is encoded by Folate Hydrolase 1 (FOLH1) gene located on short arm of
chromosome 11. PSMA has a 19-amino-acid intracellular portion (Figure 1-1E-i), a 24amino-acid transmembrane portion (Figure 1-1E-ii) and a 707-amino-acid extracellular
portion (Figure 1-1E-ii,iii and iv) (Maurer, Eiber et al., 2016, Rahn, Watkins et al., 2012b).
PSMA is expressed in the renal tissue and duodenum and contributes to the required
enzymatic processing of dietary folates (Rahn, Slusher et al., 2012a). Also, a lower level
of PSMA in the brain tissue activates metabotropic glutamate receptor (mGluR) pathway
activity by facilities N-acetyl-l-aspartyl-l-glutamate (NAAG) cleavage (Rahn et al.,
2012b). In prostate tissue, PSMA can activate signaling phosphatidylinositol 3-kinase
(PI3K) /Akt (Protein Kinase B)/mammalian target of rapamycin (mTOR) pathway by
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release of glutamate (Kaittanis et al., 2018). Figure 1-1C&E illustrates the enzyme actions
of PSMA. The catalytic domain of PSMA (Figure 1-1E-iv) facilitates glutamate release
from the cleavage of vitamin B9 or folic acid. Free glutamate induces mGluR I activation
and activates PI3K through phosphorylation of p110β. Finally, activated PI3K leads to
activation of Akt-mTOR and it elevates protein synthesis and growth (Palamiuc &
Emerling, 2018).
A representative PSMA immunohistochemistry (IHC) staining of normal prostate tissue
from Human Protein Atlas (HPA) on Figure 1-1D displays PSMA expression is highest in
AR-positive epithelial cells of the prostate. This work, and previously published papers,
show AR-positive cell lines are PSMA-positive as well. On the contrary, AR-negative cell
lines are PSMA-negative. However, PSMA is not positively regulated by androgen (Bakht
et al., 2019a, Bakht, Oh et al., 2016, Miyahira, Pienta et al., 2018).

1.1.5

Prostate cancer (PC)

The prostate gland is derived from the endoderm germ layer during development and
represents a major site for the incidence of malignancy in comparison to its adjacent tissues
such as the seminal vesicle with mesoderm origin. PC is defined as a malignant neoplasm
of the prostate tissue (Shen & Rubin, 2019). Almost all of PCs originate in the epithelial
cells of the prostate gland, a form of cancer classified as a carcinoma. Glandular
carcinomas, such as the prostate gland, are commonly referred to as adenocarcinomas.
There are rare incidences of prostate sarcomas that originate from cells within the prostate
that originate from the surrounding mesenchyme, as well as prostate lymphomas which
arise from lymphocytes. Huggins and Hodges (Huggins & Hodges, 1941) discovered the
androgen-dependent landscape of PC in the 1940s (Sathianathen, Konety et al., 2018). As
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a consequence of that seminal study and understanding the key role of androgen signaling
in progression of PC, the androgen deprivation therapy (ADT) has become the backbone
for treating PC (Mateo, Fizazi et al., 2018).

1.1.6

PC progression

At early stages of PC, cancer cell with a higher AR activity exist among benign prostate
gland cells, while higher PSA secretion as an AR-regulated protein is detectible in blood
(Figure 1-2A-B). Most men in this level respond to ADT and prostatectomy, but their
disease progresses and becomes resistant to further hormonal therapy. Progressively, these
cancer cells start to increase and spread to the nearby the stroma leading tumor formation
(Figure 1-2C). Ultimately, the cancer cells could metastasis to other organs such as lymph
nodes the bones (Wein et al., 2011).

1.1.7

Castration-resistant prostate cancer (CRPC)

Most patients with metastatic disease managed with ADT eventually relapse with
CRPC (Heidenreich, Bastian et al., 2014). In CRPC, AR signaling is suggested to be
reactivated in several ways, including (i) AR overexpression, (ii) AR splice variants such
as AR-V7 (iii) AR gene mutations leading to improvement of the ligand response such as
ARF876L, (iv) crosstalk with other signaling pathways (v) alterations in expression of
transcriptional coactivators resulting in improved AR transactivation (vi) prostate cancer
stem-like cells (Bakht, Oh et al., 2017a, Wang et al., 2017). Effective and safely
administrable AR pathway inhibitor(ARPI), enzalutamide (MDV3100) is a promising
treatment option for metastatic CRPC. Also, some recent data suggests the potential of
enzalutamide therapy for localized PC (Caffo, Maines et al., 2014). Neuroendocrine prostate
cancer (NEPC)
7

Lineage switching or cellular plasticity is an important developmental process that allows
a particular genotype to profoundly alter its phenotype in response to changes in the
microenvironment (Nijhout & development, 2003). For cancer cells, cellular plasticity is
an opportunistic adaptation to reprogram to a phenotypic version capable of evading cancer
treatments to maintain their proliferation (Davies, Beltran et al., 2018b).
The effectiveness of next-generation ARPIs such as abiraterone acetate and
enzalutamide, in managing CRPC has been obstructed by the development of cellular
plasticity-dependent resistance to ARPIs. In other words, this developed resistance to
ARPIs is due to the capability of PC cells to modify their phenotype to adopt ARindependent pathways for proliferation. Around 25% of CRPC tumors treated by ARPI
undertaken lineage switching to become AR-independent and to obtain a neuroendocrine
(NE) feature. These highly aggressive tumors are named neuroendocrine prostate cancer
(NEPC) and show re-activation of developmental or embryonic pathways (Davies et al.,
2018b). In this work, patients with lack of NE histopathology or gene signature are referred
as adenocarcinoma PC (AdPC).
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Figure 1-2 A schematic of PC progression and PSA alterations from normal to NEPC.
(A) The normal prostate gland has a well-organized structure and it prevents secretion of PSA in
to the blood. (B) Early stage PC is diagnosed after elevation of PSA to above 4 ng/mL increasing
angiogenesis. (C) The appropriate ADT approach leads to PSA level decline and ARPI starts as
soon as CRPC is formed. (D) CRPC tumor is not responsive to ARPI and PSA is drastically
increasing. So, second generation of ARPI is prescribed and PSA level decreases. (E) PSA level
surveillance is not effective anymore due to the possibility of NEPC formation.
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There are two hypotheses that explain the potential origin of NEPC. First, that normal
neuroendocrine cells of the prostate gland undergo oncogenic alteration and form NEPC.
Second, AdPC cells undergo transdifferentiation or lineage switching to a NEPC lineage
by genetic and epigenetic changes. Recent studies on NEPC profoundly favors the
transdifferentiation hypothesis (Beltran, Prandi et al., 2016b). NEPC tumors express
common NE markers such as neuron specific enolase (NSE; gene ENO2), chromogranin
A (CHGA) and synaptophysin (SYP) (Parimi, Goyal et al., 2014). NEPC is associated with
the loss of RE1-silencing transcription factor (REST) due to alternate splicing by the RNA
splicing factor serine/arginine repetitive matrix 4 (SRRM4). SRRM4 plays a key role in
transdifferentiation of AdPC to NEPC under ARPI (Li, Donmez et al., 2017). SRRM4 can
induce NEPC in patients treated by ARPI through compromising the function of genes
such as REST (Li et al., 2017). The elevation of SRRM4 and the loss of REST are
indicators of treatment-induced NEPC.

1.1.8

PC screening

The main aim of PC screening is to identify aggressive PCs as early as possible to prevent
progression to a metastatic state, a goal which will ultimately increase survival rates (Smith,
Andrews et al., 2018). Screening for PC using a multiparametric protocol by incorporation
of transrectal ultrasound (TRUS) data, digital rectal examination (DRE), and PSA level
was suggested in the early 1990s (Cooner, Mosley et al., 1990).Multiparametric magnetic
resonance imaging (mpMRI) is commonly combined for local staging (Descotes, 2019).
PSA screening has considerable shortcomings such as false-positive results that cause
redundant biopsies. Recently, US Preventive Services Task Force and Canadian Task Force
on Preventive Health Care modified PC screening protocols to decrease chance of over10

diagnosis and overtreatment of PC (Jin, 2018, Rendon, Mason et al., 2017). Currently, the
DRE and PSA test followed by a TRUS guided biopsy is still standard of care for PC
screening around the world, including Canada (Rendon et al., 2017). Technetium
scintigraphy is also the current gold standard for detection of bone metastasis (Descotes,
2019).

1.1.9

Gleason scoring and PC staging

In 1966, Dr. Donald Gleason established his grading scoring system for PC (Gleason,
1966). The Gleason system assigns grades are based on the level of similarity between PC
and benign tissues. If the apparent PC tissue is similar to benign prostate tissue, a grade of
1 is apportioned (Sathianathen et al., 2018). If the malignant tissue seems hugely abnormal,
a grade of 5 will be assigned. Grades 2 to 4 have characters in between these extremes.
Since PC regularly have zones with dissimilar grades, a grade is assigned to the 2 regions
that contribute the most of malignancy. Finally, these 2 grades are added to yield the
Gleason score. So, the first number given is the grade that is most common in the tissue
(Partin, Kattan et al., 1997). To increase agreement between needle biopsy and radical
prostatectomy pathology, a Modified Gleason scoring classification was published by
Epstein et al.in 2016 and accepted by the WHO (Epstein, Egevad et al., 2016, Harnden,
Shelley et al., 2007).
As the most prevalent staging protocol for PC is the American Joint Committee on Cancer
(AJCC) proposed tumor nodes metastasized (TNM) system (Table 1-1). The TNM system
for prostate cancer is based on five main points: (i) The extent of the main (primary) tumor
(T category) (ii) Whether the cancer has spread to nearby lymph nodes (N category) (iii)
Whether the cancer has metastasized to other parts of the body (M category) (iv) The PSA
11

level at the time of diagnosis (v) The Gleason score (Mottet, Bellmunt et al., 2017). The
main stages of PC range from I (1) to IV (4) (Grignon, 2018).

1.1.10 PC in Canada
In 2019, it is estimated that 22,900 men will be diagnosed with PC in Canada. Also, 4,100
men will die from PC, which denotes 9% of all cancer deaths in men in 2019. In other
words, on average, 63 Canadian men will be diagnosed with PC, and 11 Canadian men will
die from PC every day.
In Canada, the five-year net survival for prostate cancer is among the highest of all cancers
at 95%. Estimates from the United States (where five-year survival is closer to 97%),
indicate that survival for early stage disease is almost 100%. But it is much lower for
cancers that presented with distant metastases (stage IV) at diagnosis (29%) (Table 1-1).
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Table 1-1 AJCC stating protocol and percent distribution of PC at diagnosis in Canada.
Stages of PC and percent distribution of PC by stage at diagnosis in Canadian men between
2011–2015 (CCSsACoC, 2014, Grignon, 2018, Mottet et al., 2017).
AJCC Stage

I

Stage grouping

cT1, N0, M0
Grade Group 1 (Gleason score 6 or less)
PSA less than 10
cT2a, N0, M0
Grade Group 1 (Gleason score 6 or less)
PSA less than 10

Percent distribution of PC
at diagnosis in Canada

22.5%

pT2, N0, M0
Grade Group 1 (Gleason score 6 or less)
PSA less than 10

IIA

cT1, N0, M0
Grade Group 1 (Gleason score 6 or less)
PSA at least 10 but less than 20
cT2a or pT2, N0, M0
Grade Group 1 (Gleason score 6 or less)
PSA at least 10 but less than 20

IIB

cT2b or cT2c, N0, M0
Grade Group 1 (Gleason score 6 or less)
PSA less than 20
T1 or T2, N0, M0
Grade Group 2 (Gleason score 3+4=7)
PSA less than 20

IIC

T1 or T2, N0, M0
Grade Group 3 or 4 (Gleason score 4+3=7 or 8)
PSA less than 20

IIIA

T1 or T2, N0, M0
Grade Group 1 to 4 (Gleason score 8 or less)
PSA at least 20

IIIB

T3 or T4, N0, M0
Grade Group 1 to 4 (Gleason score 8 or less)
Any PSA

IIIC

Any T, N0, M0
Grade Group 5 (Gleason score 9 or 10)
Any PSA

IVA

IVB

51.9%

Any T, N1, M0
Any Grade Group
Any PSA
Any T, any N, M1
Any Grade Group
Any PSA
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13.8%

8.6%

1.2

NUCLEAR MEDICINE AND MOLECULAR IMAGING

Nuclear imaging modalities can be commonly classified into positron emission
tomography (PET) and single photon emission computed tomography (SPECT). Unlike
CT or MRI, which visualize structure or anatomic of tissue, PET and SPECT generate
functional or metabolic images of tissues (Khan & Gibbons, 2014, Mayles, Nahum et al.,
2007). The fusion of therapy and diagnostics to optimize the efficacy and safety of
therapeutic regimes is named theranostics and is a rapidly growing approach. Currently,
PET and SPECT images are regularly fused with other structural imaging modalities, such
as CT or MRI, to correlate functional with anatomical information (Azad & Cook, 2016,
Maurer, 2008).

1.2.1

PC Molecular Imaging

A variety of radiopharmaceuticals are being used for PC molecular imaging and we can
classify them in these categories: (i) bone imaging, (ii) PC metabolic activity, and (iii)
PSMA expression.
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Table 1-2 summarises these options. Also, the flow-chart on Figure 1-3 represents the

significance of molecular imaging in the management of PC (Evangelista, Briganti et al.,
2016).

Table 1-2 An overview of the radiopharmaceuticals for PC molecular imaging.
Adopted with permission (Glumac, 2019).
Radiopharmaceutical

Target

Indication

Regulatory Status

FDG

Glucose
metabolism

minimal use in PC, only
used when other tracers are
not available

FDA approved,
August 5, 2004

NaF

Osteoblastic
activity

Known or suspected osseous
lesions

FDA Approved,
January 26, 2011
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C-choline

Cell membrane
metabolism

High-risk staging,
biochemical relapse at high
PSA levels

FDA approved,
September 12,
2012

11

C-acetate

Fatty acid
synthesis

Useful for monitoring
recurrence after focal
therapy, unreliable in
biochemical recurrence, not
as effective as other agents
on the market

Under
investigation

Fluciclovine

Amino acid
transport

High-risk staging,
biochemical relapse at high
PSA levels

FDA approved,
May 27, 2016

FDHT

AR

Early stage disease detection
and prognosis

Under
investigation

anti-PSMA ligands

PSMA

Multiple stages including
biochemical relapse at low
PSA

Under
investigation

15

Figure 1-3 Flow-chart depicting the roles of molecular imaging in the diagnostic management
of prostate cancer patients.
ADT, Antiandrogen therapy; BRT, brachytherapy; CT, chemotherapy; EBRT, external beam
radiotherapy; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RP,
radical prostatectomy; sLND, salvage lymphadenectomy; 18F, fluorine-18; 11C, choline-11; 68Ga,
gallium-68; 111In, indium-111. Reprinted with permission (Evangelista et al., 2016)
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1.2.2

PSMA-targeted molecular imaging
PSMA is an appealing target for molecular imaging and therapy of PC since it is

over-expressed in a majority of PC tumors and metastatic lesions (Rai, Baum et al., 2016).
Targeting PSMA is feasible by a wide variety of radio-ligands (Jadvar & Ballas, 2018,
Kopka, Benešová et al., 2017, Rowe, Gorin et al., 2017). The PSMA ligands can also be
labelled with therapeutic radionuclides which can irradiate PSMA-expressing cells
(Boegemann, Schrader et al., 2017). In spite of the promissing applications of PSMA for
many forms of advanced PC there are clinical reports supporting that PSMA-targeted
imaging is not able to define NEPC tumors (Chakraborty, Tripathi et al., 2015, Parimi et
al., 2014, Sheikhbahaei, Afshar-Oromieh et al., 2017, Tosoian, Gorin et al., 2017a,
Usmani, Ahmed et al., 2017).

1.2.3

Somatostatin receptor-targeted molecular imaging

The somatostatin receptor subtype 2 (SSTR2) is prevalent in the majority NE tumors and
DOTATOC and DOTA-TATE radioligands with affinity to SSTR are radiotracers for
delineation of NE tumors (Poeppel, Binse et al., 2011). Recently, Gofrit et al. suggested
that 68Ga-DOTA-TATE might be a potential option for NEPC imaging (Gofrit, Frank et
al., 2017). Interestingly, Usmani et al. compared

68

Ga-PSMA versus

68

Ga-DOTA in a

NEPC patient and reported that the NEPC tumor and metastatic lesions have avid uptake
of 68Ga-DOTA while the 68Ga-PSMA uptake was faint and inconclusive (Usmani et al.,
2017). These same reports suggest that targeting somatostatin receptor type 2 (SSTR2)
could be an alternative diagnostic target for NEPC patients.
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1.2.4

FDG metabolic imaging

Similar to glucose, 18F-fluorodeoxyglucose (FDG) is actively transported into the cell by
the protein family of glucose transporters (GLUTs), encoded by SLC2A genes, followed
by phosphorylation by hexokinase (Haberkorn, Ziegler et al., 1994). In some types of
tumors a positive correlation has been reported between FDG uptake and the levels of
specific GLUTs and hexokinases (Avril, 2004, Haberkorn et al., 1994, Yang, Zhong et al.,
2019). FDG-positron emission tomography (PET) is a well-accepted approach for
delineation of proliferative and poorly-differentiated/dedifferentiated NE-tumors (Bozkurt,
Virgolini et al., 2017). Despite this, FDG-PET has been considered ineffective in assessing
metastatic tumor burden and monitoring therapy response (Jadvar, 2016). Previous clinical
reports indicate that PCs with a phenotype similar to NE tumors can be more amenable to
imaging by FDG rather than PSMA-targeting radioligands.
1.3

NANOMEDICINE

Nanotechnology has been used in most areas of biomedical research (Bawarski,
Chidlowsky et al., 2008, Davis & Shin, 2008, Fontanarosa & Bauchner, 2015, Liu,
MacDonald et al., 2013, Morris, Molina et al., 2015, Sitharaman, 2016), with many
applications in cancer therapy (Chen, Gu et al., 2015, Currell & Bellringer, 2016, Ferrari,
2005, Mirkin, Meade et al., 2015, Wang, Yang et al., 2008), it is expected that
nanomedicine could play important diagnostic and therapeutic roles in oncology (Bregoli,
Movia et al., 2016). Nanomedicine may improve screening and therapeutic options for
different cancers by exploiting the unique characteristics of each tumor (Hammond, 2016,
Kuncic, 2015, Tong & Kohane, 2016, Wicki, Witzigmann et al., 2015, Xu, Ho et al., 2015).
Thereby, nanomedicine may represent a vehicle for the delivery of important aspects of
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personalized cancer management (Collins & Varmus, 2015, Hammond, 2016, Herrmann
& Rösslein, 2016).
1.4

HYPOTHESES AND OBJECTIVES

In Chapter 2, the correlation between expression of FOLH1, NEPC marker genes and
SSTR2 is investigated. We evaluated the transcript abundance for FOLH1 and SSTR2 genes
as well as NE markers in a variety of models. This study scrutinizes the reliability of using
PMSA as a target for molecular imaging of NEPC. The observed elevation of SSTR2 in
NEPC supports the possible ability of SSTR2-targeted imaging for follow-up imaging of
low-PSMA patients and monitoring for NEPC development. Specifically, the following
topics will be investigated:
•

The possible inconsistency of PSMA gene expression in high grade CRPC.

•

The correlation between the expression of PSMA and common NE biomarker
genes.

•

The apparent suppression of PSMA in treatment-induced NEPC.

•

The possible inverse correlation between the expression of FOLH1 and SSTR2.

•

The survival rates of patients with enhanced expressions of NE-makers.

In Chapter 3, the association between NE gene signature and FDG uptake-associated genes
including glucose transporters (GLUTs) and hexokinases is evaluated, with the goal of
providing a genomic signature to explain the reported FDG-avidity of PSMA-suppressed
tumors. We measured glucose uptake in a NE-induced in vitro model and a zebrafish model
by non-radioactive imaging of glucose uptake using fluorescent glucose bioprobe, GB2Cy3. Spesifically, the following topics will be investigated:
19

•

The identification of a NE-like PC (NELPC) subset among a cohort of primary and
metastatic PC samples.

•

The assumable differential expression of SLC2A and HK in NEPC and NELPC.

•

The possible association of SLC2A and HK expression with Gleason score and
biochemical recurrence in NELPC.

•

The possible used of zebrafish model for in vivo imaging of glucose uptake.

In Chapter 4 as a review chapter, a wide variety of nanostructure-based prostate cancer
research using radiation technology and nuclear medicine is discussed. Radionanomedicine
is a recently coined term for the simultaneous application of either radiation technology or
nuclear medicine with nanomedicine. Radioexosomics is our suggested term for the study
of exosomes functions, cytotoxicity, cancerogenicity, and biodistribution using radiation
technology and nuclear medicine tracing technology. In addition, we will present what is
currently known about the function of exosomes in PC. The review concludes by
summarizing the current status and future perspectives of radionanomedicine and
radioexosomic for understanding PC biology and the perspectives in targeting strategies,
drug delivery, molecular imaging and therapy.
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CHAPTER 2 : NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER
LEADS TO PSMA SUPPRESSION
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2.1

INTRODUCTION

The main treatment protocol for patients suffering from castration-resistant prostate cancer
(CRPC) is androgen receptor pathway inhibition (ARPI). Selection pressure and lineage
plasticity of ARPI can lead to neuroendocrine (NE) differentiation of prostate
adenocarcinoma (AdPC), promoting the more prevalent subtype of CRPC which is termed
treatment-induced neuroendocrine prostate cancer (NEPC) (Davies, Beltran et al., 2018a).
It has been speculated that mutations in lineage regulators such as retinoblastoma 1 (Rb1)
and tumor protein 53 (p53) could also pave the way of ARPI to confer AdPC lineage
plasticity and development of NEPC (Chen, Dong et al., 2018).
Due to the presumed androgen receptor (AR)-negativity of NEPC tumors,
treatment options are restricted to platinum- and cisplatin-based combinations and median
survival of NEPC patients is much lower than patients with AdPC (Vlachostergios &
Papandreou, 2015). Early identification of NEPC and novel targeting options could be
beneficial. Despite the positive implications of PSMA for many forms of advanced AdPC
there are clinical reports supporting that PSMA-targeted imaging is not able to delineate
NEPC tumors (Chakraborty et al., 2015, Parimi et al., 2014, Sheikhbahaei et al., 2017,
Tosoian et al., 2017a, Usmani et al., 2017). In four specific cases NEPC patients did not
show substantial PSMA-radioligand uptake, in one case this was described due to a downregulation of PSMA (Chakraborty et al., 2015, Parida, Tripathy et al., 2018, Tosoian et
al., 2017a, Usmani et al., 2017). To date the relevance of these clinical reports have not
been investigated.
In this study we use bioinformatic datasets, cell lines and patient-derived xenograft
(PDX) models to study the correlation between expression of the PSMA gene, FOLH1, NE
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biomarkers and SSTR2. This work supports that NEPC tumors have a distinct PSMAsuppressed signature and demonstrate the possibility that SSTR2-targeted imaging could
be an alternative diagnostic target for this aggressive form of prostate cancer.
2.2

MATERIAL AND METHODS

2.2.1

Cell lines and Cell Culture

The LNCaP and DU-145 cell lines were purchased from ATCC (Manassas, VA, USA).
The high passage LNCaP cell line (LNCaP-HP) was a generous gift from Dr. Dora CavalloMedved of University of Windsor. LNCaP and LNCaP-HP cells were grown in RPMI 1640
in the presence of 10% fetal bovine serum (FBS). DU-145 cells were grown in Eagle's
minimum essential medium (E-MEM) supplemented with 10% FBS. For induction of NEtransdifferentiation, LNCaP cells were cultured in RPMI1640 medium with 10% charcoalstripped serum (CSS) over 10 passages during 4 weeks. LNCaP cells were cultured in
RPMI medium supplemented with 10% CSS when treated with 10 µM enzalutamide (ENZ)
from Selleckchem (Houston, TX, USA).

2.2.2

Plasmids and Infection

Small hairpin RNA (shRNA)-based p53 knockdown was attained by transducing LNCaP
cells with p53 shRNA lentiviral particles and transduction control cells were produced by
using control shRNA lentiviral Particles. pLKO1 shp53-targeting shRNA (Addgene,
#19119) (MOI=8) and pLKO1-control (Addgene, #8453) as an empty backbone were gifts
from Dr. Bob Weinberg of Massachusetts Institute of Technology. The lentiviral
production was previously described (Al Sorkhy, Ferraiuolo et al., 2012). 10,000 cells were
seeded in fully supplemented growth media in 24-well plates for 24 hours. Cells were
starved by removing serum from the media, followed by the use of 1 mg/ml polybrene
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(Santa Cruz, sc-134220) and MOI 3 of the specific vector used. Infected media was
changed to fully supplemented media 24 hours after infection. Cells were incubated with
1mg/ml puromycin (Sigma, P8833) 48 hours after infection for 72 hours to allow for
puromycin selection. Media is thereafter changed every 48 hours with puromycin included.
The isolated single cell clones were cultured in RPMI medium supplemented with 10%
CSS.

2.2.3

Immunoblotting and Immunocytochemistry
Immunoblotting and immunocytochemistry techniques were described previously

(da Silva, Botsford et al., 2016, Li et al., 2017). In brief: Cells were lysed in TNE buffer
(50mM Tris, 150mM NaCl, 5mM EDTA) with protease inhibitors (leupeptin 2µg/mL,
aprotinin 5µg/mL, PMSF 100µg/mL). Protein concentrations were assessed using the
Bradford assay and equal amounts of protein were analyzed using SDS-PAGE and
transferred to PVDF membranes. Membranes were blocked for 1 hour at room temperature
in 1% BSA and incubated in primary antibody overnight at 4°C, followed by secondary at
a concentration of 1:10,000 for 1 hour at room temperature. Visualization was conducted
using chemiluminescent peroxidase substrate (Pierce) as per manufacturer’s instructions.
Images were captured on Alpha Innotech HD 2 using AlphaEase FC software.
For immunocytochemistry primary antibodies were diluted in 3% BSA-0.1%
Tween-20 in 1x PBS and used at a concentration of 1:200. Secondary antibodies were used
at a concentration of 1:750. Slides were imaged using the LEICA DMI6000 inverted
microscope with LAS 3.6 software.
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Actin antibody was purchased from Chemicon-Millipore (MAB150 1R). PSMA
(D4S1F) was purchased from Cell Signaling (12702). The secondary rabbit and mouse
antibodies were purchased from Sigma. SSTR2 (sc-365502), AR (sc-815), NSE (sc271384) and p53 (sc-53394) were purchased from Santa Cruz Biotechnology.

2.2.4

Cell Proliferation Assay

Cell proliferation assay was conducted by plating 20,000 LNCaP cells per well of a 24well cell culture plate in 500 µL of RPMI medium supplemented with 10% CSS and treated
with vehicle control (DMSO) or enzalutamide (10 µM) for 6 days. Cell numbers were
counted using trypan blue exclusion and using a haemocytometer; counts were also verified
using a TC10 automated cell counter (Biorad).

2.2.5

Colony Formation Assay

To evaluate the anchorage-independent ability of LNCaP cells with different levels of
PSMA, the colony formation assay was used. LNCaP cells were seeded in 6-well plates at
a concentration of 2500 cells per well. They were then cultured for 1 week in RPMI
supplemented with CSS, followed by treatment for 1 more week with vehicle control
(DMSO) or enzalutamide (10 µM). The cell colonies were fixed with 4%
paraformaldehyde and stained with crystal violet (Sigma-Aldrich). Colonies were
photographed and scored via NIH ImageJ software.

2.2.6

Neurite length measurement and statistical analysis

Neurite length for each separate cell was measured by manual tracing and determined using
NIH ImageJ software as previously described (Ding, Li et al., 2015). The neurites were
defined as a process with lengths equivalent to one diameters of a cell body. The percentage
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of neurite-bearing cells was calculated from the total number of counted cells (n = 3, ~1000
cells measured).

2.2.7

Quantitative Real-Time PCR Analysis

RNA was isolated using Qiagen RNeasy Plus Mini Kit as per manufacturer’s instructions.
cDNA was synthesized using Superscript II (Invitrogen) as per manufacturer’s
instructions. SYBR Green detection (Applied Biosystems) was used for real-time PCR and
was performed and analyzed using Viia7 Real Time PCR System (Life Technologies) and
software. The primers used are listed on Table 2-1.
Table 2-1 Sequence of primers used for RT-PCR studies.
Gene

Forward primer (5’-3’)

Reverse primer (5’-3’)

FOLH1

GGAGAGGAAGTCTCAAAGTGCC

TGGTTCCACTGCTCCTCTGAGA

GAPDH

GGAGTCAACGGATTTGGT

GTGATGGGATTTCCATTGAT

2.2.8

In Silico Dataset

Using Human Protein Atlas (www.proteinatlas.org) (Thul, Åkesson et al., 2017, Uhlen,
Zhang et al., 2017), cBioPortal webportal (http://cbioportal.org) (Gao, Aksoy et al., 2013)
and the web-portal UALCAN (Chandrashekar, Bashel et al., 2017) we evaluated the
transcript abundance for PSMA gene (FOLH1), prostate specific antigen (PSA) gene
(KLK3), four well-known NE biomarker genes including neuron specific enolase (NSE)
gene (ENO2), CD56 gene (NCAM1), synaptophysin gene (SYP), chromogranin A gene
(CHGA).
An multiple AdPC genomic datasets named Cambridge Carcinoma of the Prostate
App (http://bioinformatics.cruk.cam.ac.uk/apps/camcAPP) was used in this study
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(Dunning, Vowler et al., 2017). The web-portal UALCAN (Chandrashekar et al., 2017)
was also used which focuses on TCGA level 3 RNA-seq and clinical data from 31 cancer
types. We analyzed relative expression of genes across AdPC tumors and normal samples,
based on Gleason grading system using this resource. In addition, we used the Beltran
dataset (Beltran, Prandi et al., 2016a) including 34 AdPC samples from 33 patients and 15
NEPC samples from 10 patients. Table 1 provides an overview of the datasets used in
analysis.
The expression of PSMA protein was examined in a variety of organs using the
Human Protein Atlas (www.proteinatlas.org). Two anti-PSMA antibodies including
HPA010593 (Sigma-Aldrich) and CAB001451 (Novocastra) were used for visualization
and measurement of PSMA in all major tissues and organs (n = 45) in the human body,
supplemented with RNA-sequencing data for 31 of the tissues. The same antibodies used
for immunohistochemistry images of AdPC tissues in different stages and each annotated
by pathologists (Thul et al., 2017, Uhlen et al., 2017).

2.2.9

The Survival Data and Pairwise-Correlations of Gene Expression

The specialized web interface, Cambridge Carcinoma of the Prostate App
(http://bioinformatics.cruk.cam.ac.uk/apps/camcAPP/) as a source for multiple AdPC
genomic datasets was used in this study (Dunning et al., 2017). Table 1 provides an
overview of the datasets used in this analysis (Ross-Adams, Lamb et al., 2015, Taylor,
Schultz et al., 2010). The Cambridge (Ross-Adams et al., 2015) cohort involved 358 fresh
frozen samples from 156 patients comprising; 125 primary prostate cancer from radical
prostatectomy with matched benign tissue, 64 matched germline genomic DNA (gDNA),
19 CRPC from channel transurethral resection of the prostate, 13 with matched germline
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gDNA, and 12 independent benign samples from holmium laser enucleation of the prostate.
The camcAPP was used for recursive partitioning-based survival analysis and KaplanMeier plots, pairwise-correlations of gene expression and heatmaps of gene expression
data.
Survival data and heatmaps were generated using camcAPP, which is implemented
in R code as a Shiny application (Dunning et al., 2017). Kaplan-Meier biochemical relapsefree survival plots were generated using a recursive partitioning (RP) analysis named
unbiased recursive partitioning (Hothorn, Hornik et al., 2006). This conditional inference
framework was used to determine if the samples could be split into groups based on the
expression data from each of the genes of interest. The algorithm tailored for our case can
be described as follows: a statistical test of independence was run between gene expression
levels and the survival times. When the p-value of initial test of independence (ITI) was
found to be less than 0.05, an optimal cutoff point was determined in the expression data
such that a weighted log-rank statistic (a loss function based on log-rank) comparing the
two groups resulting from dividing the sample of patients by the cutoff point would be
maximized. Afterwards, the samples were split at the optimal cutoff point on the expression
scale and represented as a log-rank comparing those two groups. When the algorithm did
not confirm dependence between survival times and gene expression, we split samples into
two groups based on median expression level of the gene. In the cases with ITI p-values
more than 0.05 we are unable to state a definitive relationship between the expression of
the gene and survival. The value quoted on the Kaplan-Meier plots of this manuscript
indicate where the recursive partitioning algorithm has found two distinct groups of
samples as high and low expression levels and the log-rank test was employed to identify
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statistical difference between the high and low expressing groups. Pearson correlation was
used for pairwise-correlations of the studied gene expression analysis.

2.2.10 Animals and PDX models
Fresh AdPC or NEPC tissues from patients were grafted under the kidney capsules of
non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. This study
followed the ethical guidelines stated in the Declaration of Helsinki, specimens were
obtained from patients with their informed written consent approved by the Institutional
Review Board of the University of British Columbia (UBC). Animal care and
experimental procedures were carried out in accordance with the guidelines of the
Canadian Council on Animal Care (CCAC) under the approval of the Animal Care
Committee of the UBC.
The expression of the PSMA gene in 5 AdPC PDX models (LTL-313-B, LTL-313B-R, LTL-418, LTL-418-R and LTL-331-7) and 2 NEPC PDX models (LTL-331-7-R and
LTL-352) was studied by real time PCR analysis. Transcription of FOLH1 and SSTR2
genes in 18 PDX models including 3 NEPC models were analyzed. Transcriptomic analysis
for all PDX models, with the exception of the LTL331-331R castration time-series
samples, was achieved by GE 8×60K microarray and transcriptomic analysis of the
LTL331-331R time-series performed using RNA-sequencing data (Akamatsu, Wyatt et al.,
2015b, Ci, Hao et al., 2018). We previously characterized and validated these models as
having AdPC and NEPC mRNA and protein signatures (Li et al., Lin, Wyatt et al., 2014a,
Nabavi, Saidy et al., 2017).
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2.2.11 Statistical Analysis
All of the in vitro experiments were performed in triplicates and repeated three times. All
in vitro and in vivo results are expressed as the mean ± standard error of the mean (SEM).
In the box whisker plots, the line inside each box is the median, upper box border represents
the 75th quartile, lower box border represents the 25th quartile and whiskers represent the
range. Statistical analysis was done using the GraphPad Prism 5.01 software (GraphPad
Software, CA, USA). Differences between the two groups were compared by unpaired
Student’s t-test. One-way ANOVA followed by a Benjamini-Hochberg, Tukey, or
Newman-Keuls multiple comparison test was used to compare differences among multiple
groups. The false discovery rate (FDR) less than 0.05 considered as significant in
Benjamini–Hochberg adjustment. The levels of significance were set at p < 0.05 as *,
p < 0.01 as ** and p < 0.001 as ***
For quantification of FOLH1 heatmaps, -0.5<Z-score and +0.5>Z-score are
considered as suppression and upregulationthresholds for gene expression. The percent of
patients with suppression (Z-score≤ -0.5), no alteration (-0.5 <Z-score< +0.5) and
upregulation (Z-score≥ +0.5) of FOLH1 in each group of samples were calculated. Total
number of patients with enhanced expression of gene of interests were counted and set as
the maximum value. Of the maximum value patients, those who were co-upregulated with
FOLH1 were categorized as “Upregulation”, while those whose FOLH1 status did not
change or was down-regulated were categorized as “No Alteration” and “Suppressed”
respectively. The values for all three categories were then divided by the maximum value
and graphed under their respective categories.
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2.3

RESULTS

2.3.1

High Grade CRPC Has Inconsistent Expression of The PSMA Gene (FOLH1)

FOLH1 expression was highly up-regulated in prostate tissue and relatively upregulated in
both the hippocampus and salivary gland (Figure 2-1A). Similarly, protein level of PSMA
was higher in prostate tissue than all other organs and tissues. Only the kidney, small
intestine and duodenum reached medium levels of protein expression (Figure 2-1B).
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Figure 2-1 The evaluation of PSMA levels in different human organs.
The level of PSMA in a variety of human organs in (A) mRNA and (B) protein level from version
18, Human Protein Atlas (HPA) (https://www.proteinatlas.org/ENSG00000086205FOLH1/tissue).

As compared to a spectrum of other cancer types (Gao et al., 2013), FOLH1 expression is
highly enhanced in AdPC (Figure 2-2A). AdPC patients with enhanced expression of
FOLH1 gene have a significant poorer survival rate in MSKCC (Taylor et al. 2010) dataset
(Figure 2-2B). Similarly, the Cambridge (Ross-Adams et al. 2015) dataset displayed
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differential outcomes for men with low versus high FOLH1 expression (log-rank p=0.047)
however the initial test of independence shows no significance and hence conclusions
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Figure 2-2 The levels of FOLH1 in a variety of cancers and its correlation with survival.
(A) Alteration of FOLH1 in a variety of cancers from cBioPortal dataset (Gao et al., 2013) (B, C)
Survival rate of patients with low vs high PSMA gene expression among patients of (b) Cambridge
(Ross-Adams et al., 2015) and (C) MSKCC (Taylor et al., 2010) datasets.

With the aim of exploring PSMA gene levels during progression of AdPC to clinically
relevant CRPC, the Michigan and Cambridge datasets were used and gene expression
levels studied (Figure 2-3 A, B). The Michigan dataset (Grasso, Wu et al., 2012) showed
that there is an expected rise from normal to AdPC tissue in expression of FOLH1 but there
was no statistically significant difference between hormone-responsive AdPC and CRPC
tumors (Figure 2-3 A). A cluster of samples with very low expression of the PSMA gene
is observable in CRPC samples. Similarly, Figure 2-3B illustrates an increase from benign
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to hormone-responsive tumor in the expression of FOLH1 in the Cambridge dataset and,
interestingly, there was a significant drop in expression when transitioning to CRPC. To
further explore this inconsistency, we evaluated the expression of FOLH1 by Gleason
grading score (Figure 2-3C) in TCGA dataset (Chandrashekar et al., 2017).
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Figure 2-3 Expression of PSMA at varying grades of CRPC.
(A, B) Box-whisker plots showing the expression of FOLH1 gene in three different classes of
samples from (A) Michigan (Grasso, et al. 2012) and (B) Cambridge (Ross-Adams et al., 2015)
datasets (C) The expression of FOLH1 during progression of AdPC based on Gleason score from
TCGA dataset generated by web-portal UALCAN (Chandrashekar et al., 2017). One-way
ANOVA followed by unpaired t-tests were performed with Benjamini–Hochberg adjustment for
multiple test correction; **p < 0.01 and***p < 0.001, n.s.: no significant. (D) Heatmap plot of the
mean expression levels of FOLH1, PSA gene (KLK3) and four major clinically significant NE
marker genes including among patients of Cambridge (Ross-Adams et al., 2015) datasets. (E)
Percent of patients with suppression (Z-score≤+0.5), no alteration (-0.5<Z-score<+0.5) and
upregulation in gene expression (Z-score≥+0.5) of FOLH1 in each group of samples. (F-J)
pairwise-correlations of the studied gene expression and Pearson correlation analysis from
Cambridge (Ross-Adams et al., 2015) datasets.

From benign tissue (normal) to Gleason score (GS) 8 FOLH1 levels steadily increase and
then they remain unchanged between the transition from 8 to 9. Samples with GS of 10
showed no significant elevation in comparison with the normal samples. While the sample
size (n=4) prevents definitive conclusions for GS 10, the observed fall in FOLH1
expression supports the possibility of a suppression in high-grad AdPC. Collectively, this
led us to conclude that expression of FOLH1 in high grade CRPC is variable and that there
is a need to question whether FOLH1 expression and PSMA protein levels are effective in
determining progression to the highest grades of AdPC.

2.3.2

An Inverse Correlation Between The Expression of FOLH1 And Common NE
Biomarker Genes

Figure 2-3D shows the mean expression levels of FOLH1, PSA gene (KLK3) and NE
marker genes over 144 patients. As we expected, KLK3 and FOLH1 expression had a direct
correlation where 49% of patients with an enhanced expression of KLK3 also showed an
enhanced expression of FOLH1 gene (Figure 2-3E). In contrast, an inverse correlation
between FOLH1 and NE biomarker gene expression was identified. Particularly,
suppression of FOLH1 was observed in 65% and 53% of patients who were overexpressing
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the NE genes ENO2 and NCAM1, respectively. The numbers of patients with enhanced
expression of genes of interest based on level of FOLH1 gene expression are presented on
Table 2-2.
In Figure 2-3F-J, this relationship was further characterized through the use of a Pearson
correlation. On Figure 2-3G&H, a strong inverse correlation between FOLH1 and ENO2
and NCAM1, is prevalent (r= -0.46 and -0.33), while correlation between FOLH1 and the
other NE-markers was not significant. Figure 3f shows there was a significant direct
correlation between FOLH1 and KLK3 genes (r=0.41). Table 2-3 provides confidence
interval (CI) parameters of these gene correlations. Fig. 4 shows the mean expression levels
of FOLH1, NE genes, AR and AR target genes. Similar to the PSA gene (KLK3), AR and
some other AR target genes such as KLK2, FKBP5, CAMKK2 and NKX3-1 are also
inversely correlated with FOLH1 expression. The overall regression analysis led us to
conclude that PSMA and NE biomarkers are inversely correlated.
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Table 2-2 The numbers of patients with enhanced expression of genes of interests based on
level of FOLH1 gene expression.
Gene
name

Patients with
Suppression of
FOLH1

Patients with no
alteration of
FOLH1

KLK3

Total number
of patients
with z-score
>+0.5
39

5

15

Patients with
upregulation of
FOLH1
expression
19

ENO2

46

35

12

10

NCAM1

31

22

1

8

SYP

52

19

11

18

CHGA

23

9

8

5

Table 2-3 An overview of Pearson correlations between FOLH1 and other studied genes and
calculated confidence interval parameters.
Dataset

Gene

Pearson Correlation
Correlation
(r)

MSKCC
(Taylor et al.
2010)

Cambridge
(Ross-Adams
et al. 2015)

CHGA
ENO2
KLK3
NCAM1
SYP
SSTR2
CHGA
ENO2
KLK3
NCAM1

-0.012
-0.460
0.413
-0.329
-0.035
-0.182
-0.069
-0.567
0.505
-0.417

Coefficient of
determination
(r2)
0.0001
0.2114
0.1704
0.1085
0.0012
0.0034
0.0048
0.3215
0.2551
0.1746

SYP
SSTR2

0.202
-0.502

0.0409
0.2525

* Lower confidence level
** Upper confidence level
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t-statistic

p-value

95% CI of
Correlation
LCL* UCL**

-0.15668
-7.00394
6.132873
-4.72098
-0.47877
-2.514
-0.9804
-9.66179
8.214723
-6.45597

0.87
<0.0001
<0.0001
<0.0001
0.63
0.01
0.32
<0.0001
<0.0001
<0.0001

2.900693
-8.159

0.004
<0.0001

-0.156
-0.566
0.286
-0.452
-0.179
-0.318
-0.206
-0.654
0.393
0.5263
0.065
-0.599

0.133
-0.338
0.526
-0.194
0.109
-0.395
0.070
-0.464
0.601
-0.296
0.332
-0.390

2.3.3

Treatment-induced NEPC correlates with PSMA suppression

Previously we showed SRRM4 can induce NEPC in patients treated by ARPI through
compromising the function of genes such as REST (Li et al., 2017). The elevation of
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Figure 2-4 Correlative analysis of FOLH1 with SSRT2 and NE genes.
(A) The heatmap plot of the mean expression levels of FOLH1, NE genes and somatostatin
receptor-2 gene (SSTR2) expression among patients of Cambridge dataset (Ross-Adams et al.,
2015) (Method to calculate distances is euclidean). (B) The percent of patients with suppression
(Z-score≤+0.5), no alteration (-0.5<Z-score<+0.5) and upregulation (Z-score≥+0.5) of FOLH1 in
each group of samples. (C) Pairwise-correlation of treatment-induced gene expressions and Pearson
correlation analysis from Cambridge dataset (Ross-Adams et al., 2015) (27). (D) The expression of
SSTR2 during progression of AdPC based on Gleason score from TCGA dataset generated by webportal UALCAN (Chandrashekar et al., 2017). One-way ANOVA followed by a t-test was
performed with Benjamini–Hochberg adjustment for multiple test correction; **p < 0.01 and***p
< 0.001, n.s.: no significant. (E) The comparison of SSTR2 expressions between AdPC and NEPC
samples of Beltran dataset (Beltran et al., 2016a) Error bars reflect SEM and Student’s t-test was
performed.
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Figure 2-5A-B show that when SRRM4 is upregulated FOLH1 is highly suppressed and,
conversely, when REST is upregulated FOLH1 expression is enhanced. Specifically, the
suppression of FOLH1 was observed in 57% of patients who were overexpressing SRRM4,
while only 15% of patients who were overexpressing REST had suppression of FOLH1.
As summarized on Table 2-4, Beltran dataset (Beltran et al., 2016a) patient samples are
histologically characterized as AdPC and NEPC. Figure 2-5C shows NEPC has
significantly lower expression of FOLH1 (p<0.001) as compared to AdPC. Following this
we analyzed the association between FOLH1 and SRRM4 expression in NEPC samples
and found that a significant (p=0.011) inverse correlation was present between the two
biomarkers (r=-0.358) (Figure 2-2D). Also, Figure 2-5E shows FOLH1 directly correlated
to REST expression (r=0.561). The relationship of SRRM4 and REST to FOLH1
collectively supports that treatment-induced NE transdifferentiation correlates with
suppressed PSMA gene expression.
Table 2-4 An overview of the prostate cancer datasets used in this study.
Dataset
name

Source

Platform: gene
expression

Platform:
copy
number

Sample size
and tumor
type

Cambridge
2015

Ross-Adams et al. (Ross-Adams,
Lamb et al.)

Illumina HT12

Illumina
Omni 2.5

125 Primary
19 Advanced

MSKCC
2010

Taylor et al. (Taylor, Schultz et al.)

Affymetrix Human
1.0 ST

Agilent
244k

109 Primary
19 Advanced

Michigan
2012

Grasso et al. (Grasso et al., 2012)

Agilent Whole
Human 44k

Agilent
105k/244k

59 Primary
32 Advanced

TCGA for
prostate
cancer

UALCAN (Chandrashekar et al.,
2017)

Illumina

Illumina
HiSeq
2000N

497 Primary

Beltran
2016

Beltran et al. (Beltran et al., 2016a)

Agilent 2100

Illumina
HiSeq

34 AdPC
15 NEPC
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Figure 2-5 Analysis of FOLH1, SRRM4 and REST in tumor datasets.
(A) The heatmap plot of the mean expression levels of FOLH1, SRRM4 and REST genes among
patients of Cambridge dataset (Ross-Adams et al., 2015). (B) The percent of patients with
suppression (Z-score≤+0.5), no alteration (-0.5<Z-score<+0.5) and upregulation(Z-score≥+0.5) of
FOLH1 in each group of samples. (C) The comparison of FOLH1, SRRM4 and REST expressions
between AdPC and NEPC samples of Beltran dataset (Beltran et al., 2016a). Error bars reflect
SEM and Student’s t-test was performed (D, E) The relationship between FOLH1 and SRRM4
levels in NEPC samples in Beltran dataset (Beltran et al., 2016a) by Pearson correlation analysis.
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2.3.4

An inverse correlation between the expression of FOLH1 and SSTR2

The heatmap plot in Figure 2-6A displays NE marker genes clustered together at the top
which showed less difference while SSTR2 and FOLH1 represented the largest difference;
consequently, Figure 2-6B demonstrates that more than 61% of patients with elevation of
SSTR2 are FOLH1-suppressed. Figure 2-6C and Table 3 show a modest inverse correlation
between SSRT2 and FOLH1 (r = -0.50). Figure 2-6D shows that from benign tissue
(normal) to (GS) 9, FOLH1 is suppressed while there is an evidence of a 2-fold increase in
the expression of SSTR2 at GS of 10 (p<0.05). SSRT2 level in NEPC sample showed no
suppression (Figure 2-6E). This led us to conclude that the observed suppression of FOLH1
could be accompanied by SSTR2 gene overexpression at high grade CRPC.
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Figure 2-6 Correlative analysis of FOLH1 with SSRT2 and NE genes.
(A) The heatmap plot of the mean expression levels of FOLH1, NE genes and somatostatin
receptor-2 gene (SSTR2) expression among patients of Cambridge dataset (Ross-Adams et al.,
2015) (Method to calculate distances is euclidean). (B) The percent of patients with suppression
(Z-score≤+0.5), no alteration (-0.5<Z-score<+0.5) and upregulation(Z-score≥+0.5) of FOLH1 in
each group of samples. (C) Pairwise-correlation of treatment-induced gene expressions and Pearson
correlation analysis from Cambridge dataset (Ross-Adams et al., 2015) (27). (D) The expression of
SSTR2 during progression of AdPC based on Gleason score from TCGA dataset generated by webportal UALCAN (Chandrashekar et al., 2017). One-way ANOVA followed by a t-test was
performed with Benjamini–Hochberg adjustment for multiple test correction; **p < 0.01 and***p
< 0.001, n.s.: no significant. (D) The comparison of SSTR2 expressions between AdPC and NEPC
samples of Beltran dataset (Beltran et al., 2016a) Error bars reflect SEM and Student’s t-test was
performed.
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10

2.3.5

NEPC-Like Patients Have Significantly Worse Survival Rates Than NonNEPC-Like Patients.

Kaplan Meier survival curves studying high and low expression levels of the PSA gene,
KLK3, fail to reveal any consistent correlation with patient survival over two different
datasets (Figure 2-7A& Figure 2-8A).
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Figure 2-7 The probability of freedom from biochemical recurrence (BCR) of prostate cancer
patients grouped according to the gene expression levels.
Kaplan Meyer survival curves for high and low expression levels of (A) KLK3 (B) ENO2 (C)
CHGA (D) NCAM1 (E) SYP (F) SRRM4 (G) REST (H) SSTR2 genes generated by MSKCC (Taylor
et al., 2010).
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Figure 2-8 The probability of freedom from biochemical recurrence of prostate cancer
patients grouped according to the gene expression levels.
Kaplan Meier survival curves for high and low expression levels of (A) KLK3 (B) ENO2 (C) CHGA
(D) NCAM1 (E) SYP (F) SRRM4 (G) REST (H) SSTR2 genes generated by Cambridge dataset
(Ross-Adams et al., 2015).

SSTR2 and NE genes including ENO2 and NCAM1 did not correlate with a difference in
BCR (Figure 2-7B, D, H and Figure 2-8 B, D, H). Figure 2-7E& Figure 2-8E show that
enhanced expression of SYP was associated with decreased relapse-free survival (poor
outcome) in both of studied datasets (log-rank p<0.05). Enhanced expression of CHGA
was also correlated with poor outcome in MSKCC (Taylor et al. 2010) dataset (Figure
2-7C). Similarly, Kaplan–Meier analysis of CHGA in Cambridge (Ross-Adams et al., 2015)

dataset showed clear partitioning for men with low versus high CHGA expression (logrank p=0.025) however the initial test of independence was not significant and hence no
conclusion can be drawn from this dataset (ITI p=0.28).
The evaluation of treatment-induced NEPC, SRRM4, showed the SRRM4 high group had
a significantly (log rank p=0.046) poorer prognosis than SRRM4 low group (Figure 2-7F).
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This trend continued with its down-stream target, REST; where REST high group had a
significantly (log rank p=0.0056) better prognosis than REST low group (Figure 2-7G).
The relationships observed in MSKCC (Taylor et al., 2010) dataset were not consistently
observed in the Cambridge (Ross-Adams et al., 2015) dataset. Results found nonsignificant in the Cambridge dataset do not prove that there is no relationship with survival
for those genes, but this inconsistency provides evidence that the effects of several genes
on survival are not clear-cut.
In all, the trends in Kaplan Meier survival curves in Figure 2-7and Figure 2-2B, C imply
that NE markers, especially treatment-induced NEPC, could be clinically significant in
determining survival rates and correlate with poorer prognosis. Further examination into
FOLH1 and KLK3 is required before a definitive correlation can be made for these genes.

2.3.6

PSMA Suppression And SSTR2 Overexpression in NE-Induced AdPC Cell
Line

The levels of PSMA, SSTR2, AR and NSE were measured in three different cell line
models representing androgen-sensitive AdPC, CRPC and NEPC (Figure 2-9A,B)
LNCaP cell line as an AR-positive cell line has wild-type p53 and it is considered a
typical model for androgen-sensitive AdPC (Chen et al., 2018). In addition, LNCaP-HP
as a high passage LNCaP cell line could be a model of CRPC due to its androgen
insensitivity while it has positivity for AR (Unni, Sun et al., 2004). AR-negative DU145
cells, suggested to be used as a NEPC model, contain two different point mutations in the
TP53 gene (Phe223Leu and Val274Phe), one on either allele, producing nonfunctional
protein product (Chappell, Lehmann et al., 2012, Li, Cohen et al., 2016b).
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Figure 2-9B shows the level of NSE as a NE marker has continuous elevation from AdPC

to NEPC. AdPC and CRPC in vitro models are AR and PSMA positive while NEPC
models are PSMA and AR negative. SSTR2 has significantly higher level in DU145 model.
To examine the impact of NE transdifferentiation of AdPC on PSMA levels we
used the LNCaP cell line which mimics the phenotype of NEPC cells when maintained
overtime in steroid-reduced conditions (Zelivianski, Verni et al., 2001). LNCaP cells
maintained in 10% CSS for one month have an altered phenotype compared to control cells
maintained in 10% FBS (Figure 2-9C). Almost 75% of the CSS-FBS treated LNCaP cells
(LNCaP) extended neurites, whereas less than 10% of control or LNCaP-FBS cells bore
neurites (Figure 2-9D). Additionally, both the mean length of the longest neurite and the
total neurite length were significantly increased in LNCaP-CSS cells compared with the
LNCaP-FBS (Figure 2-9E,F). These observations indicate that LNCaP growth conditions
can play the role of in vitro models for AdPC and NEPC. The western blot assay (Figure
2-9G,H) demonstrated that SSTR2 and NSE as a NE marker protein are expressed at a

higher level in the LNCaP-CSS cell line. In contrast, PSMA, AR and p53 proteins have a
significant decline. Immunofluorescence microscopy of LNCaP cell lines support western
blot data (Figure 2-9I,L). Collectively, these data demonstrate that LNCaP-CSS are
differentiating toward a NE phenotype and that this occurs coincidentally with a decrease
in PSMA and AR levels.
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Figure 2-9 Analysis of PSMA and SSTR2 in a NEPC induced cell line.
(A-B) Western blot analyses of protein level of PSMA, SSTR2, AR, NSE and p53 in 3 different
prostate cancer cell line models. (A) immunoblotting (B) diagram showing the relative density of
protein levels (C) Representative photos of control (left) and CSS-treated (right) LNCaP cells
stained with Hoechst. Scale bar: 50 μm. (D-F) Neurites were studied under an inverted microscope:
(D) % of cells with neurites counted over 3 fields of view over 3 separate experiments. (E) Neurites
were measured using ImageJ software and longest neurite calculated. (F) Average neurite. (G-L)
LNCaP cells are treated with either FBS or CSS as indicated and level of PSMA, SSTR2, AR, NSE
and p53 were detected by (G-H) immunoblotting and (I-K) immunocytochemistry. (L) Data is
quantified using ImageJ software. Stat: Error bars reflect SEM between 3 separate experiments.
The data were analyzed by either Student’s t-test or one-way ANOVA followed by a Tukey’s
multiple comparison tests.; **p < 0.01 and***p < 0.001.

2.3.7

Development of ENZ-Resistance Following a p53-Dependent Suppression of
PSMA

Treatment of LNCaP cell line with ENZ (10 µM) resulted in an increase in PSMA protein
levels in medium containing either FBS or CSS (Figure 2-10A,B). AR levels show no
significant alteration under these conditions. Treatment with ENZ in medium
supplemented with CSS had an increase in levels of NSE. This experiment, and previously
reported data, supports that short-term exposure of LNCaP cell lines to either ENZ
treatment or serum removal cannot be a viable approach to make a clinically relevant
PSMA-suppressed in vitro model of AdPC with NE features. Recently, it had been reported
that p53 knockdown could lead to suppression of luminal markers and overexpression of
basal and NE markers (Li et al., 2017, Mu, Zhang et al., 2017). Figure 2-10C,D shows p53
knockdown of LNCaP cells in a medium supplemented in CSS for 6 days causes
suppression AR and PSMA. DU145 as an AR and PSMA negative cell line have a
significant higher level of NSE (p<0.01). Due to overexpression of NSE and suppression
of PSMA we used the p53-knockdown cell line as a model of low-PSMA cancer with NE
features for the next steps of our experiments. The LNCaP cell line transduced with
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shControl is also referred to as high-PSMA cell line. Figure 2-10E shows that LNCaP cells
with low level of PSMA have slightly higher proliferation during 6 day treatment with the
control vehicle (DMSO) but it was not statistically significant (p=0.65). During ENZ (10
µM) treatment, low-PSMA cells demonstrate a higher growth rate (p=0.0048) and on the
sixth day of cell counting low-PSMA cell numbers were 2.8 times higher than high-PSMA
cells. It can be inferred that low-PSMA cells are less sensitive to ENZ (10 µM) than highPSMA cells over this 6 day experiment. In addition, we tested sensitivity of LNCaP cells
with different levels of PSMA using colony formation assay (Figure 2-10F) and find that
low-PSMA cells have more colonies formed under ENZ (10µM) treatment than treatment
of cells with high PSMA. Therefore, low-PSMA cells were less sensitive to ENZ treatment,
supporting the hypothesis that suppression of PSMA, as found in NEPC, correlates with
more aggressive disease.
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Figure 2-10 Analysis of treatment response to ENZ following a p53-dependent suppression of
PSMA.
(An-B) Western blot analyses of protein level of PSMA, SSTR2, AR and NSE in LNCaP cell line treated
with vehicle control (DMSO) or ENZ (10 µM) supplemented with either FBS or CSS for 6 days (A)
representative immunoblot (B) the relative density of protein levels. (C, D) Western blot analyses of protein
level of PSMA, SSTR2, AR, NSE and p53 in LNCaP cell line transduced with annotated shRNA
supplemented with CSS for 6 days. (C) representative immunoblot (D) the relative density of protein levels.
(E) Growth curve of LNCaP cell lines with different levels of PSMA following treatment with vehicle control
(DMSO) or ENZ (10 µM) in supplemented with CSS. (F, G) The colony-forming ability of high-PSMA and
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low-PSMA seeded in 10% CSS for 1 week and treated with either ENZ(10 µM) or DMSO for 1 more week.
(F) representative wells (G) quantification of the number of the colonies using CellProfiler software. (H)
Schematic of the impact of ARPI, hormonal deletion and loss of p53 on PSMA, AR and SSTR2 based on the
obtained data in figs. 9 and 10. Error bars reflect SEM between 3 separate experiments. The data were
analyzed by either Student’s t-test or one-way ANOVA followed by a Tukey’s multiple comparison tests.;
**p < 0.01 and***p < 0.001.

Figure 2-10H shows a schematic of the associations in changing gene expression found
using in vitro models. Hormone depletion, which is modeled by serum deprivation,
suppresses PSMA, AR and p53 levels and elevates levels of SSTR2. ARPI which is
modeled by treating cells with ENZ, showed no alteration of AR or SSTR2 but increased
levels of PSMA. A p53 knockdown in vitro model, supports that suppression of PSMA and
AR are associated with p53-dependent cellular plasticity and that this is independent of
SSTR2 levels.

2.3.8

NEPC Has a Distinct FOLH1-Suppressed Signature in PDX Models

Following pathological investigation, patient tumours were stratified into either AdPC or
NEPC phenotypes put into PDX mouse models and studied before or after castration
(schema Figure 2-11A-C). Significant suppression of FOLH1 was observed in the LTL331R-G7 and LTL-352 mice which were found to progress to NEPC, as compared to those
mice lacking NE marker expression (p<0.05) (Figure 2-11D). There was a wide spectrum
of FOLH1 expression in different AdPC models. In the LTL-313-B model, after castration
of mice which can mimic treatment-induced relapse in the form of CRPC, we observed a
2.4 folds elevation in FOLH1. However, in the LTL-418 model there was no significant
alteration in FOLH1 expression. For simulation of treatment-induced NEPC, after inducing
NE to LTL-331-7 model as a CRPC model, a 2.1 times suppression of FOLH1 was
observed. Similarly, the PDX model obtained by direct engraftment of tissue from a NEPC
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metastases sample had significantly lower FOLH1 expression in comparison with all AdPC
models.
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Establishment and analysis of AdPC and NEPC PDX mouse models. (A, B, C and D) Schematic of the established PDX mice models of AdPC and NEPC
(adapted, with permission, from Lin et al. (2014)). (D) The levels of FOLH1 in different PDX models. One-way ANOVA followed by a Newman–Keuls multiple
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Figure 2-11 Establishment and analysis of AdPC and NEPC PDX mouse models.
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2-12D shows of the expression levels of FOLH1 and SSTR2 through the progression to

NEPC. In the AdPC model FOLH1 is found at a maximum level and SSTR2 at a minimum
level. Following castration up to 8 weeks there is low fluctuations in the transcription of
both of the genes. However, on 8th week, a sharp decline in FOLH1 and a profound
elevation of SSTR2 starts. The terminally differentiated NEPC model has a minimal
transcriptional level of FOLH1 and maximal transcription of SSTR2.

2.3.9

PSMA Levels Fail to Adequately Predict NE Transdifferentiation of High
Grade AdPC

Similar to its RNA, PSMA protein level could have a variable series of staining levels of
low grade (Figure 2-13A, D), medium grade (Figure 2-13B, E) and high grade (Figure
2-13C, F) AdPC. These staining patterns imply a series of possible progression paths for

AdPC progression and eventual NEPC. On Figure 2-12E, we proposed five possible models
for alteration of PSMA during progression of AdPC. Model 1 is the classical model of
PSMA expression in which the level of PSMA correlates positively with the stage of AdPC,
our data supports that this model is not entirely represented in the data. Model 5 is a
representation of a de novo occurrence of NEPC, which shows poor onset PSMA staining.
However, models 2 and 3 are relevant as AdPC progression pathways that lead to NE
transdifferentiation and subsequent loss of PSMA. In addition, model 4 is representation
of a constant poor PSMA staining which against its low abundance is still capable of
detecting metastatic sites. The HPA dataset PSMA antibody staining patterns for AdPC
progression led us to conclude that model 2 is the most likely progression pattern for the
treatment-induced NEPC.
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Figure 2-12 NEPC represents a distinctive FOLH1-supressed signature in a series of PDX
model.
(A-B) Transcriptomic profiles from the PDX models (15 adenocarcinomas vs. 3 NEPCs), (A)
heatmap showing the clustering among all PDX samples (B) the average level of FOLH1 and
SSTR2 suggests a unique down-regulation of FOLH1 in NEPC PDX tumors while SSTR2 levels
are slightly increased. The data were analyzed by Student’s t-test (C) Schematic of development of
LTL-331R as terminally differentiated NEPC PDX model following castration of hormonesensitive LTL-331 PDX model. The time points at which tumors were collected along progression
to NEPC are illustrated by blue color arrows. Some elements of this figure were produced using
Servier Medical Art image bank (www.servier.com). (D) Transcription of FOLH1 and SSTR2
during NE transdifferentiation in the LTL331 system highlighting the suppression of FOLH1 and
enhanced expression of SSTR2 during development of NEPC as a result of hormone depletion. (E)
Possible models of alteration of PSMA level during progression of AdPC. Schema shows possible
kinetic changes in PSMA level (Y axis) during progression from low, medium and high grade
AdPC.
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Figure 2-13 The evaluation of PSMA levels.
IHC images of PSMA protein expression staining in different stages of AdPC. Image available
from version 18, Human Protein Atlas (HPA) (https://www.proteinatlas.org/ENSG00000086205FOLH1/pathology).

2.4

DISCUSSION

The development of NE phenotype following hormone depletion in LNCaP cell line is a
well-studied observation (Shen, Dorai et al., 1997, Yuan, Veeramani et al., 2006b). Liu et
al. (Liu, Wu et al., 2012) reported that hormone depletion suppresses AR and PSMA levels
in LNCaP cells, however they did not evaluate the expression of NE makers. Suppression
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of AR and overexpression of NE makers in LNCaP following p53 knock-down in LNCaP
cell has also been described recently (Li et al., 2017, Mu et al., 2017). In this manuscript,
we report the suppression of PSMA and overexpression of NSE and SSTR2 in LNCaP cell
line following hormone depletion and loss of p53.

2.5

CONCLUSION

The use of potent antiandrogens and lineage plasticity may contribute to the increasing
prevalence of NEPC, an aggressive and hormone resistant form of AdPC. While PSMA
targeting is a promising approach for the nuclear imaging and therapy of many forms of
aggressive AdPC, our data based on transcriptome analysis of tumor samples, cell line
models and PDX mice models supports that PSMA (FOLH1 gene) levels are not consistent
with all forms of high grade CRPC. Our in vitro data showed a significant suppression of
PSMA as a result of both of hormone depletion, loss of p53 and lineage plasticity. A
PSMA-suppressed NEPC cell line model showed higher colony formation and resistance
to ARPI by ENZ. Our data further shows that induced NE transdifferentiation correlates
with an elevated level of the protein SSTR2. SSTR2 levels appear to elevate due to
hormone depletion but are not affected by altered cellular plasticity. PDX data support
these conclusions, showing an inverse correlation between the expression of the PSMA
gene and SSTR2 gene. Specifically we find declining PSMA and increasing SSTR2 gene
expression occurring during the development of CRPC and becoming more pronounced in
terminally differentiated NEPC. Collectively, this study cautions on the reliability of using
PMSA levels as a diagnostic target for molecular imaging in advanced treatment-induced
NEPC. Our work supports the recommendation that SSTR2-targeted imaging approaches
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may permit more accurate monitoring of PSMA-suppressed patients due to SSTR2positivity of NEPC tumors.
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CHAPTER 3 : DIFFERENTIAL EXPRESSION OF GLUCOSE TRANSPORTERS AND
HEXOKINASES IN PROSTATE CANCER WITH A NEUROENDOCRINE
GENE SIGNATURE: A MECHANISTIC PERSPECTIVE FOR FDG IMAGING
OF PSMA-SUPPRESSED TUMORS
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3.1

INTRODUCTION

The androgen receptor (AR) plays a central role in regulating the transcriptional events
driving prostate cancer (PC) progression and development of metastatic castration-resistant
prostate cancer (mCRPC) (Stelloo, Bergman et al., 2019). AR-inhibition is an effective
therapeutic approach for most patients at different stages of PC. Although the incidence of
de novo neuroendocrine (NE) PC (NEPC) is considered rare, several emerging forms of
PC with low-levels of AR are identified. The suppression and low activity of AR in these
patients is largely associated with a NE gene signature (NEGS) and resistance to ARinhibition (Bluemn, Coleman et al., 2017, Stelloo, Nevedomskaya et al., 2018).
AR-directed therapy of mCRPC could promote cellular plasticity and development
of an AR-suppressed phenotype similar to NEPC which manifests the histopathology of
NE disease (Beltran, Prandi et al., 2016c). Another emerging phenotype of mCRPC is ARnull and NE-null, classified as double-negative PC (DNPC) (Bluemn et al., 2017). A recent
molecular subtyping of PC patients with no history of AR-directed therapies identified a
NE-positive subtype with low chromatin binding and activity of AR. These patients have
been referred to as NE-like PC (NELPC) since they do not represent the NE-histopathology
(Alshalalfa, Liu et al., 2019, Stelloo et al., 2018).
AR regulates the expression of FOLH1 gene encoding the transmembrane protein,
prostate-specific membrane antigen (PSMA). PSMA-targeted molecular imaging and
therapy are transforming the landscape of PC management (Hope, Goodman et al., 2019,
Sheikhbahaei et al., 2017). Despite the impactful implications of PSMA, there are clinical
reports that suggest that PSMA-targeted imaging does not effectively visualize NEPC
tumors (Chakraborty et al., 2015, Sheikhbahaei et al., 2017, Tosoian, Gorin et al., 2017b).
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Pre-clinical studies confirmed that the induction of lineage plasticity by AR-inhibition
leads to NE-transdifferention and suppression of PSMA (Bakht, Derecichei et al., 2019b).
Recent case reports illustrate NEPC delineation may be more feasible by FDG than
PSMA-radioligands (Parida et al., 2018, Perez, Hope et al., 2019) and Spratt et al. (Spratt,
Gavane et al., 2014) demonstrated the utility of FDG-PET for NEPC imaging.
Interestingly, Thang et al. (Thang, Violet et al., 2018) screened patients with 68Ga-PSMA11 and FDG-PET and they identified a subset of patients with low PSMA-radioligand
uptake and high FDG uptake.
Development of non-radioactive glucose analogs enabling the delineation of the
glucose uptake of tumors have been studied using a variety of optical approaches mostly
in mouse models (Cheng, Levi et al., 2006). PC xenograft studies in zebrafish are coming
to the forefront as a cost-effective and time-efficient model for drug screening, and the
fluorescent glucose bioprobe GB2-Cy3 has been used to monitor glucose uptake in a
zebrafish model (Lee, Lee et al., 2011, Melong, Steele et al., 2017). However, the feasibility
of monitoring of glucose uptake in PC in a zebrafish model has not been evaluated.
In this work we used data mining approaches, cell lines and patient-derived xenograft
(PDX) models to study expression levels of glucose uptake-associated genes including
GLUTs and hexokinases in NEPC and NELPC to provide a genomic rationalization for the
previously reported FDG-avidity of PSMA-suppressed PC tumors. We also present the
feasibility of non-radioactive in vivo imaging of glucose uptake using a zebrafish model.
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3.2

MATERIAL AND METHODS

3.2.1

Cell Culture

The LNCaP cell line was purchased from ATCC and grown in RPMI-1640 in the presence
of 10% fetal bovine serum. Progression to NEPC was achieved by culturing LNCaP cells
in RPMI1640 medium with 10% charcoal-stripped serum for 4 months. Under these
conditions, cell morphology gradually changed into a mixture of a NE-like phenotype and
a non-NE-phenotype. After 4 months, a subclone with a NE-like phenotype was isolated
(LNCaP-NEPC). LNCaP cells, maintained in RPMI-1640 + fetal bovine serum, were used
as a control and are referred to as LNCaP-AdPC.

3.2.2

Antibodies

The immunoblotting technique used was previously described (Bakht et al., 2019b).
Antibodies are as follows: actin (Chemicon-Millipoure; MAB150-1R), PSMA (Cell
Signaling; D4S1F), AR (Santa Cruz Biotechnology (SCB); sc-816), NSE (SCB; sc271384) and GCK (SCB; sc-17819) and GLUT12 (Abcam; ab100993).

3.2.3

Data Mining Analysis

Using 268 PC samples from 3 different cohorts we assessed the transcript abundance for
all of the SLC2A family (SLC2A1-14) and the HK family (HK1-4, HK4 referred to as GCK).
In addition, we monitored the PSMA gene (FOLH1), the NE marker synaptophysin gene
(SYP), SRRM4 as a positive marker of treatment-induced NEPC and REST as negative
marker of NEPC. Patients with lack of NEGS or NE histopathology are referred as
adenocarcinoma PC (AdPC).
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To assess the lineage plasticity of mCRPC, samples from a tissue acquisition
necropsy platform established at the University of Washington (UW) were used (Bluemn
et al., 2017). All rapid autopsy tissues were collected from patients who signed written
informed consent under the aegis of the Prostate Cancer Donor Program at the UW and the
Institutional Review Board of the UW approved this study. We classified our mCRPC
subtypes as AdPC (AR+/NE−), AR-suppressed AdPC (ARlow/NE−), NEPC (AR−/NE+), and
DNPC (AR−/NE−). In addition, we used the Beltran cohort (Beltran et al., 2016c) with
histologically confirmed mCRPC-AdPC and mCRPC-NEPC samples. We identify a
NELPC subset among AdPC tumors from the Memorial Sloan Kettering Cancer Center
(MSKCC) cohort (Taylor et al., 2010) using the meta-signature of prototypical high-grade
NEPC (Tsai, Lehrer et al., 2017). Gene set enrichment analysis (GSEA) was performed on
the identified subsets using gene sets downloaded from the Molecular Signatures Database
(Subramanian, Tamayo et al., 2005).

3.2.4

Mice PDX Models

Fresh PC tissues from patients were grafted under the kidney capsules of non-obese
diabetic/severe combined immunodeficient mice. Institutional Review Board and Animal
Care Committee of the University of British Columbia approved this study and all subjects
signed a written informed consent. We previously characterized and validated these models
(Akamatsu, Wyatt et al., 2015a).

3.2.5

GB2-Cy3 Synthesis
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Synthesis of a glucose bioprobe GB2-Cy3 was previously reported with some
modifications (Korbel, Lalic et al., 2001, Lee et al., 2011, Park, Lee et al., 2007). Full
experimental details are provided in the Appendix A.

3.2.6

In Vitro Glucose Uptake Imaging

For in vitro imaging for glucose uptake by GB2-Cy3 we adopted published protocols (Lee
et al., 2011). Briefly, 50,000 LNCaP cells were seeded in 12 well glass-bottom dishes
(Corning) overnight at 37°C. Cells were washed 2 times with PBS and incubated for 1 hour
at 37°C in glucose-deficient DMEM medium. Cells were treated with 7 μg/mL GB2-Cy3
and 100 ng/mL Hoechst 33342 (Thermo Scientific) in glucose-deficient DMEM at 37 °C
for 5, 10 and 30 minutes, respectively. Cells were washed twice with PBS and prepared for
live imaging by adding 1 mL of PBS. Fluorescence images were obtained on a LeicaDM
IL microscope (Wetzlar, Germany). Cy3 signal was quantified using ImageJ and the mean
fluorescent signal measurement from 30–40 cells.

3.2.7

In Vivo Glucose Uptake Imaging

Wild-type zebrafish (Danio rerio) were maintained following the Canadian Council on
Animal Care Guidelines. In vivo uptake of GB2-Cy3 in was visualized in a zebrafish model
by modifications of previous protocols (Melong et al., 2017, Park, Um et al., 2014). Full
experimental details are provided in the Supplemental Material. This study was approved
by the University of Windsor Animal Care Committee. Eggs were collected after
fertilization and kept at 33°C for 48 hours post-fertilization (hpf). Three hours before
implantation, attached LNCaP cells were incubated with 100 ng/mL Hoechst 33342 for 40
minutes at 37°C. After staining, cells were rinsed twice with PBS and RPMI-10% CSS
medium was added.
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At 48 hpf embryos were anesthetised with 0.168 mg/mL of Tricaine (Sigma,
MS222). 100-150 labelled cells/ 9 nL were loaded into glass capillary needles and injected
into the yolk sac of each embryo using a Nanoject II (Fisher Scientific). After injection,
embryos were kept in water at 33°C. At 72 hpf the xenograft was examined using a Leica
fluorescent stereoscope. 84 hpf embryos were treated with 250 μg/mL GB2-Cy3 at 33°C
for 2 hours, followed by a water wash and a 15 minutes incubation. Embryos were then
anesthetized, and imaged. Fold change in tumour foci and glucose uptake were quantified
by total DAPI and Cy3 fluorescence respectively. The image for each embryo was
imported into ImageJ, converted to a 32-bit greyscale, and the threshold was adjusted to
eliminate background pixels.

3.2.8

Statistical Analysis

Statistical analysis was done using GraphPad Prism (CA, USA). The results are expressed
as the mean ± standard error of the mean (SEM). The box-whisker plots show the median
(horizontal line), the interquartile range (margins of box) and the absolute range (vertical
line). Differences between two groups were compared by unpaired Student’s t-test. Oneway ANOVA followed by a Benjamini-Hochberg or Tukey adjustment. Neurite length was
measured by manual tracing and determined using NIH ImageJ software as previously
described (Bakht et al., 2019b, Ding et al., 2015). Pearson correlation was used for nearest
neighbor analysis and pairwise-correlation of the studied genes. Kaplan-Meier plots and
heatmaps were generated using camcAPP (Dunning et al., 2017) and Broad Institute
Morpheus software (MA, USA).
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3.3

RESULTS

3.3.1

Differential Expression of FOLH1, SLC2A and HK in mCRPC

Figure 3-1A shows that expression of SLC2A12 and FOLH1 are the nearest neighbors to
AR (r > 0.6, P < 0.01) and GCK is the furthest neighbour (r = -0.6, P < 0.01) in the UW
cohort (Bluemn et al., 2017). We observed a significant suppression of FOLH1 in low-AR
mCRPC phenotypes including NEPC and DNPC samples (Figure 3-1B). Figure 1C shows
NEPC tumors have a 5-fold elevation of GCK (P < 0.0001) when compared to AR-positive
samples. Alternatively, Figure 3-1D demonstrates that NEPC and DNPC samples suppress
expression of SLC2A12. Figure 3-2 verifies that in the Beltran cohort (Beltran et al., 2016c)
FOLH1-suppressed NEPC samples have similar profiles of glucose transporter gene
expression. In summary, GCK gene expression is elevated and the SLC2A12 gene is
suppressed in NEPC.
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Figure 3-1 AR-negative subsets of mCRPC in UW cohort have suppressed expression of
FOLH1 and differential expression of SLC2A and HKs genes.
(A) The heatmap plot of the expression levels of SLC2A family members, HK genes, AR, FOLH1
and NE-markers sorted based on nearest neighbors clustering to AR. (B-D) The box-whisker plots
show the expression of FOLH1, SLC2A12 and GCK.
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Figure 3-2 NEPC samples of the Beltran cohort have suppressed FOLH1 and differential
SLC2A12 and GCK expression.
(A) Heatmap plot of the expression levels of SLC2A family members, HK genes, AR, FOLH1and
NE-markers sorted based on nearest neighbors clustering to AR. (B-D) The mean expression of
FOLH1, GCK and SLC2A12 in metastatic CRPC samples. Error bars reflect SEM and Student’s ttest was performed.
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3.3.2

Differential Expression of SLC2A and HK in NELPC

The meta-signature of prototypical high-grade NEPC (Tsai et al., 2017) was employed
to isolate a potential NELPC group among a population of metastatic and primary AdPC
samples lacking NEPC histopathology (Figure 3-3 and Figure 3-4). Figure 3-5A shows the
transcriptionally identified NELPC subset have shorter time to biochemical recurrence in
NELPC (log-rank P-value = 0.02). Figure 3-5B displays that a NELPC hallmark can be
observed in both primary and metastatic samples, with the more prevalent signature seen
in metastatic and high Gleason score samples. Figure 3-5C shows a lack of hallmarks of
AR response in NELPC. Figure 3-6 shows that SLC2A1, 3-5, 9, 10, 12-14 and HK1, 2 genes
cluster with REST; herein referred to as REST-clustered genes. On the other hand, SLC2A2,
6-8, 11, HK3 and CGK cluster with SRRM4 and other NE-markers; herein referred to as
SRRM4-clustered genes. Pairwise-correlation with SRRM4 expression is presented in
Figure 3-7, Figure 3-8 and Figure 3-9. Similar to NEPC, SLC2A12 and FOLH1 expression
are decreased in NELPC relative to AdPC (Figure 3-5D). GCK expression is significantly
higher in NELPC.
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Figure 3-3 A schematic of the process used to identify a NELPC subset among a population
of metastatic and primary AdPC samples.
The meta-signature of prototypical high-grade NEPC (Tsai et al., 2017) was used to identify a
potential NELPC subset among the AdPC MSKCC cohort (Taylor et al., 2010). This metasignature consists of two sets of markers for classification of AdPC and NEPC. GSEA was used to
confirm that the identified subset is characteristic of a low-AR hallmark. FDR = False discovery
rate.
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Figure 3-4 Heatmap showing the expression of NEPC markers in the NELPC subset
identified from MSKCC cohort.
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Figure 3-5 The features of NELPC subset identified from MSKCC cohort.
The NELPC subset of MSKCC cohort displays (A) shorter time to BCR, (B) more prevalence of
metastatic and high Gleason score specimens and (C) lack of AR response. Violin plots compare
the distribution of SLC2A12, GCK and FOLH1expressions in NELPC and AdPC subsets. BCR =
biochemical recurrence.
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Upregulation

Figure 3-6 Enhanced expression in the expression of SRRM4-clustered SLC2A and HK genes
in NELPC subset of patients in MSKCC cohort.
(A) Heatmap plot of the mean expression levels of SLC2A family members, HK genes, REST as
AdPC marker and SRRM4 as NE marker. (B) Violin plots compare the distribution of SLC2As and
HKs expressions in NELPC and AdPC subsets.
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Figure 3-7 SLC2A2, 6-8, 11 genes are co-expressed with SRRM4 as a treatment induced NEPC
marker.
(A-E) Pairwise-correlation of SRRM4 and the introduced SRRM4-clustered SLC2A gene expression
followed by Pearson correlation analysis generated using MSKCC PC cohort data (Taylor et al.,
2010).
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Figure 3-8 SLC2A1, 3-5, 9-12 genes as REST-clustered genes are not co-expressed with
SRRM4 as a treatment induced NEPC marker.
(A-I) Pairwise-correlation of SRRM4 and the introduced REST-clustered SLC2A gene expression
followed by Pearson correlation analysis generated using MSKCC PC cohort data (Taylor et al.,
2010).
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Figure 3-9 Pairwise-correlation of SRRM4 and HK gene expression followed by Pearson
correlation analysis generated using MSKCC PC cohort data.

3.3.3

The Association of SLC2A and HK with Gleason Score (GS) and Biochemical
Recurrence in NELPC

Figure 3-10, Figure 3-11 and Figure 3-12 depict expression levels of the studied genes
during progression of AdPC based on GS. The majority of REST-clustered SLC2A genes
and HKs are either unchanged or suppressed at high GS while SRRM4-clustered genes are
significantly increased in samples with high GS. Kaplan-Meier survival curves studying
high and low expression levels of the studied genes are represented in Figure 3-13, Figure
3-14 and Figure 3-15. The enhanced expression of SRRM4-clustered genes such as GCK

and REST-clustered gene SLC2A1 (as an exception) are significantly associated with
decreased biochemical recurrence (log-rank P-value for GCK: 0.015). Interestingly, high
levels of REST-clustered genes including SLC2A12 are associated with shorter time to
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biochemical recurrence (log-rank P-value for SLC2A12: 0.012). Table 3-1 summarises the
performed analysis on NELPC.

Figure 3-10 Enhanced expression of SRRM4-clustered SLC2A genes are correlated with
higher Gleason scores.
(A-E) Box-whisker plots showing the expression of SRRM4-clustered SLC2A genes during
progression of AdPC based on Gleason score using MSKCC PC cohort data (Taylor et al., 2010).
One-way ANOVA followed by unpaired t-tests were performed with Benjamini–Hochberg
adjustment for multiple test correction; **: P < 0.01 and ***: P < 0.001.
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Figure 3-11 Except SLC2A1 gene, the enhanced expression of REST-clustered SLC2A gene
do not correlate with higher Gleason scores.
(A-I) Box-whisker plots showing the expression of REST-clustered SLC2A genes during
progression of AdPC based on Gleason score using MSKCC PC cohort data (Taylor et al., 2010).
One-way ANOVA followed by unpaired t-tests were performed with Benjamini–Hochberg
adjustment for multiple test correction; *: P < 0.05 **: P < 0.01.
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Figure 3-12 Enhanced expression of SRRM4-clustered HK genes is associated with higher
Gleason scores.
(A-D) Box-whisker plots showing the expression of HK genes during progression of AdPC based
on Gleason score using MSKCC PC cohort data (Taylor et al., 2010). One-way ANOVA followed
by unpaired t-tests were performed with Benjamini–Hochberg adjustment for multiple test
correction; **P < 0.01; ***P < 0.001.
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Figure 3-13 Enhanced expression of SRRM4-clustered SLC2A genes including of SLC2A2,
SLC2A6, SLC2A7 and SLC2A11 is associated with shorter time to BCR.
(A-E) Kaplan-Meyer survival curves for high and low expression levels of SRRM4-clustered
SLC2A genes generated using MSKCC PC cohort data (Taylor et al., 2010). The log-rank test was
employed to identify statistical difference between the high and low expressing groups. BCR =
biochemical recurrence.
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Figure 3-14 Low levels of REST-clustered SLC2A genes including SLC2A3, SLC2A12 and
SLC2A14 expression are associated with shorter time to BCR.
(A-I) Kaplan-Meyer survival curves for high and low expression levels of REST-clustered SLC2A
genes generated using MSKCC PC cohort data (Taylor et al., 2010). The log-rank test was
employed to identify statistical difference between the high and low expressing groups. BCR =
Biochemical recurrence.
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Figure 3-15 Enhanced expression of SRRM4-clustered HK genes is associated with shorter
time to BCR.
(A-E) Kaplan Meyer survival curves for high and low expression levels of HK genes generated
using MSKCC PC cohort data (Taylor et al., 2010). The log-rank test was employed to identify
statistical difference between the high and low expressing groups. BCR = biochemical recurrence.
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Table 3-1 An overview of the studied genes in MSKCC cohort.

Gene name Protein name

Assigned
cluster

Type of alteration
in NELPC

Pearson
correlation
coefficient
with SRRM4

Probability of
freedom from
BCR
(P-value)

Gleason Score
progression
(P-value)

SLC2A1

GLUT1

REST

No alteration

0.0082

0.0026

0.001

SLC2A2

GLUT2

SRRM4

↑↑↑

0.69

0.019

0.003

SLC2A3

GLUT3

REST

↓↓

0.036

0.0042

0.0024

SLC2A4

GLUT4

REST

No alteration

0.0002

0.254

0.22

SLC2A5

GLUT5

REST

↓

0.025

0.81

0.56

SLC2A6

GLUT6

SRRM4

↑↑↑

0.79

0.039

0.01

SLC2A7

GLUT7

SRRM4

↑↑↑

0.8

0.04

0.01

SLC2A8

GLUT8

SRRM4

↑↑

0.33

0.357

0.03

SLC2A9

GLUT9

REST

↑

0.06

0.892

0.74

SLC2A10

GLUT10

REST

0.02

0.182

0.57

SLC2A11

GLUT11

SRRM4

↑↑↑

0.63

0.038

0.029

SLC2A12

GLUT12

REST

↓↓

0.098

0.012

0.013

SLC2A13

GLUT13 (HMIT) REST

No alteration

0.003

0.816

0.90

SLC2A14

GLUT14

REST

↓↓

0.02

0.0056

0.003

HK1

Hexokinase-I

REST

↓↓↓

0.26

0.0021

0.00072

HK2

Hexokinase-II

REST

No alteration

0018

0.58

0.81

HK3

Hexokinase-III

SRRM4

↑↑↑

0.78

0.036

0.019

GCK

Hexokinase-IV
(glucokinase)

SRRM4

↑↑↑

0.84

0.015

0.00032

↓
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3.3.4

SLC2A12 Suppression and GCK Overexpression are Shared Among NEPC
and NELPC

RNA-seq data from 268 PC samples from the MSKCC (Taylor et al., 2010), Beltran
(Beltran et al., 2016c) and UW (Bluemn et al., 2017) cohorts were used to stratify SLC2A114 and HK1-4 genes into NE-clustered and AdPC-clustered groups (Figure 3-16). The
intersection between the clustered genes in different cohorts and inclusion of the most
differentially expressed genes showed that GCK is the most highly expressed gene and
SLC2A12 is the most suppressed gene in samples with a NEGS.
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Figure 3-16 Among SLC2A family members and HK genes, GCK is the most highly expressed
gene and SLC2A12 is the most highly suppressed gene in samples with NE gene signature in
comparison with samples with an AdPC signature.
(A-C) The schematic showing the process of selecting the most differentially expressed genes. (A)
The RNA-seq data from 268 prostate cancer samples from MSKCC (Taylor et al., 2010), Beltran
(Beltran et al., 2016c) and UW (Bluemn et al., 2017) cohorts are used to stratify SLC2A1-14 and
HK1-4 genes into NEPC-clustered and AdPC-clustered groups. (B) Venn diagram illustrating the
intersections between the clustered genes in different cohorts. (C) The most highly differentially
expressed genes in the intersections are selected to be studied in cell lines and PDX models.
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3.3.5

NEPC Has a Distinct GCK-Upregulated and SLC2A12-Suppressed Signature
in PDX Models

The LTL331 PDX is a model of PC progression from AdPC-to-NEPC. LTL331 tumors
regress following castration, but relapse within 24 to 32 months with tumors harbouring
NEPC phenotypes (Akamatsu et al., 2015a). Figure 3-17A demonstrates that GCK
expression is minimal before progression to CRPC but reaches maximum levels following
cellular plasticity to CRPC and NEPC. Conversely, SLC2A12 expression is at its maximum
level in hormone sensitive AdPC and, with a slight fluctuation, gradually levels decrease
following castration. The expression of SLC2A12 and FOLH1 are the nearest neighbors to
AR (r > 0.6, P < 0.01) and GCK is the furthest neighbour (r = -0.87, P < 0.01) in the UW
cohort (Bluemn et al., 2017). Figure 3-17B shows in our other well characterized PDX
models consisting of 20 AdPC and 3 NEPC models that we observe significant elevation
of GCK and suppression of SLC2A12 gene expression in the NEPC models. Overall, NEPC
models have a SLC2A12-low and GCK-high signature.
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Figure 3-17 NEPC PDX models have suppressed expression of FOLH1 and differential
expressions of SLC2A12 and GCK.
(A) Transcription of the studied genes during progression to NEPC and correlation with AR. (B)
The expression of the studied genes in PDX models.
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3.3.6

Higher In Vitro Glucose Uptake in NE-induced Cell Lines

To investigate the role of progression to a NE phenotype on glucose uptake we used the
well-characterized NE subclone cell line (LNCaP-NEPC) in which NEPC cells are derived
from LNCaP cells (LNCaP-AdPC) by culturing in an androgen-depleted environment to
mimic clinical androgen-deprivation therapy (Yuan, Veeramani et al., 2006a) (cartoon of
process: Figure 3-18A; characterization of lines in Figure 3-18B-D). Figure 3-19A shows
that protein levels of the NE-marker NSE are increased in the LNCaP-NEPC, while PSMA
and AR levels are significantly decreased. The LNCaP-NEPC cell line has a significantly
higher level of glucokinase (GCK) protein and a significantly lower level of GLUT12
(Figure 3-19B).
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Figure 3-18 Development of a NE-induced LNCaP cell line.
(A) The Schematic showing the steps for progression of the LNCaP cell line to NEPC. (B)
Representative photos of control (top) and CSS-treated (bottom) LNCaP cells. (C) Neurites were
measured using ImageJ software and longest neurite calculated. (D) % of cells with neurites
counted over 3 fields of view. The results are expressed as the mean ± SEM. Differences between
two groups were compared by unpaired Student’s t-test. ***: P < 0.001. Some elements of this
figure were produced using Servier Medical Art image bank (www.servier.com). FBS = Fetal
bovine serum; CSS = Charcoal- stripped serum.
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Figure 3-19 The NE-induced LNCaP cell line represents higher glucose uptake and
differential protein levels of glucokinase and GLUT12.
(A-B) Western blot analyses of protein levels. (C-D) Quantification of GB2-Cy3 uptake and
representative images of LNCaP cells. Scale bar = 200 microns. (n = 3)
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Appendix Figure 1-8 demonstrate chemical characterization of the GB2-Cy3. Figure
3-20 illustrates GB2-Cy3 uptake and its localization in LNCaP cells. Figure 3-19C shows
the LNCaP-NEPC cell line has a higher in vitro uptake of GB2-Cy3.

Figure 3-20 GB2-Cy3 uptake and localization in LNCaP cell line.
(A) Free-Cy3 dye showed no specific uptake in LNCaP cells while GB2-Cy3 had high uptake in
cytoplasm (showed by C letter) and a minimal intensity in nuclear region (shown by N letter). (B)
Glucose competition assay using Cy3 and GB2-Cy3 shows the uptake of GB2-Cy3 by LNCaP cell
line could be inhibited as a result of increasing the concentration of glucose.
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3.3.7

Higher In Vivo Glucose Uptake in NE-induced Cell Lines

A zebrafish model was used for non-radioactive in vivo imaging of glucose uptake and
displayed higher GB2-Cy3 in engrafted LNCaP-NEPC cells (Figure 3-21). These
observations indicate that suppression of PSMA, AR and elevation of NE-markers in
LNCaP cell lines are associated with a differential level of glucose uptake, suppression of
GLUT12 and elevation of glucokinase proteins.

(n = 3) (n = 3)

Figure 3-21 The NE-induced LNCaP cell line xenografts represent higher glucose uptake in
a zebrafish model.
(A) Schematic of the experiment. (B-C) Quantification of GB2-Cy3 uptake and representative
images of embryos injected with different LNCaP cells. Red arrows show the injection sites.
Scale bar = 200 microns.
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3.4

DISCUSSION
The development of AR-indifferent and NE-positive tumor phenotypes through

divergent clonal evolution as a mechanism of resistance to AR-inhibition in mCRPC is a
well characterized concept (Beltran et al., 2016c, Bluemn et al., 2017). However, Stelloo
et al. (Stelloo et al., 2018) identified a NELPC in a treatment naïve and primary cohort.
Our work identified a NELPC subset among primary and metastatic samples with no
history of exposure to next generation AR-inhibitors. Our data also shows that the
incidence of NELPC is more prevalent in metastatic specimens. These data support that
either AR-indifferent subsets of cells can exist among AdPC that possess a greater
susceptibility for NE-transdifferentiation, or AR-indifferent, NE-like cells exist from an
early time point and are gradually selected for during treatment pressures.
3.5

CONCLUSION

NEPC, DNPC and NELPC have distinct differential expression of GLUT and HK genes.
In accordance with this, the loss of PSMA in NEPC is associated with elevated glucose
uptake.
3.6
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CHAPTER 4 : THE POTENTIAL ROLES OF RADIONANOMEDICINE AND
RADIOEXOSOMIC IN PROSTATE CANCER RESEARCH AND TREATMENT
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4.1

INTRODUCTION

Both artificial nanostructures, such as nanoparticles, as well as natural nanostructures, such
as nano-sized extracellular vesicles known as exosomes, are potential tools for approaching
personalized medicine. Artificial nanoscale particles have attracted a great deal of attention
owing to their unique electronic, optical, and magnetic properties (Salata, 2004, Sanvicens
& Marco, 2008, Sitharaman, 2016, Steichen, Caldorera-Moore et al., 2013, Sultana, Khan
et al., 2013). Natural nanostructures, like exosomes, offer unique biological advantages
such as the capacity to transport genetic materials and proteins and hence may be employed
as drug carriers (Azmi, Bao et al., 2013, Bruschi, Ravera et al., 2015, Cai, Cheng et al.,
2016, D’Incà & Pucillo, 2015, Ha, Yang et al., 2016, Hall, Prabhakar et al., 2016, Kosaka
& Ochiya, 2014, Kosaka, Yoshioka et al., 2014, Roma-Rodrigues, Fernandes et al., 2014,
Suchorska & Lach, 2016).
Prostate cancer (PC) is the most prevalent cancer in men in the western world and the
second most prevalent malignancy in the world (Center, Jemal et al., 2012, Schröder,
Hugosson et al., 2012, Siegel, Miller et al., 2015). Patients suffering from advanced PC are
usually treated with androgen-deprivation therapy (ADT) (Bolla, De Reijke et al., 2009,
Feldman & Feldman, 2001, Saad & Fizazi, 2015, Sharifi, Gulley et al., 2005, Taylor,
Canfield et al., 2009). While most patients initially respond to ADT, the disease is highly
heterogeneous, driven by different genomic alterations which represent challenges for PC
management (Aryee, Liu et al., 2013, Barbieri & Rubin, 2015, Boyd, Mao et al., 2012,
Brocks, Assenov et al., 2014a, Chandrasekar, Yang et al., 2015, Katzenwadel & Wolf, 2015,
Merseburger & Hupe, 2016, Mitani, Yamaji et al., 2011, Perner, Cronauer et al., 2015,
Saad & Fizazi, 2015, Shah, Mehra et al., 2004, Wadosky & Koochekpour, 2016, Zejnullahu,
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Arevalo et al., 2016). Patients relapsing will present with castration-resistant prostate
cancer (CRPC) which lacks effective targeted therapies. There is a need to increase our
understanding about PC biology, the driving genetic alterations, as well as the mechanisms
leading to CRPC. Expanding our understanding in these areas will improve therapeutic
options.
Radiation therapy commonly refers to the application of ionizing radiation in cancer
treatment using X-rays, gamma rays, and charged particles. The radiation may be delivered
by a radiation source outside the body of patient which refers to external-beam radiation
therapy, or it could come from radioactive material implanted in the tumor, referred to as
brachytherapy. The main purpose of radiation is to maximize the amount of radiation at
the tumor location while minimizing the exposure of normal surrounding tissues (Bakht,
Sadeghi et al., 2012, Khan & Gibbons, 2014, Mayles et al., 2007). In radiation therapy,
some challenges could be encountered such as nonspecific systemic distribution of
antitumor agents, insufficient or inefficient amount of radiation to the tumor, and the
incomplete capability to visualize therapeutic responses (Bergs, Wacker et al., 2015,
Schaue & McBride, 2015, Wang et al., 2008, Washington & Leaver, 2015).
Radionanomedicine is a recently coined term for the application of either radiation
technology or nuclear medicine with nanomedicine (Choi, Lee et al., 2016, Goel, England
et al., 2016, Lee, 2016, Lee, Im et al., 2015, Lim, Cho et al., 2015b, Muthu & Wilson, 2010,
Pratt, Shaffer et al., 2016, Satpati, Satpati et al., 2016, Soo Lee, 2016). From a nuclear
medicine point of view, the concept of radionanomedicine could be an extension of
“targeted radionuclide therapy” (Lee, 2016, Lee et al., 2015, Lim et al., 2015b). In addition,
radioexosomics is our proposed term for the study of functions, cytotoxicity,
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cancerogenicity and biodistribution of exosomes using radiation technology and nuclear
medicine tracing technology.
This chapter will summarize the utility, advantages and limitations of radionanomedicine
approaches in PC research. In addition, we will present what is currently known about the
secreted exosome by PC cells and what could be the impact of radioexosomics on the future
of PC research. We conclude by highlighting some limitations, current status and future
perspectives of radionanomedicine and radioexosomics for understanding PC biology, and
application in targeting strategies, drug delivery, molecular imaging and therapy (Bakht et
al., 2017a).
4.2

PC RADIONANOMEDICINE

PC radionanomedicine depends on the labeling of radionuclides or probes onto the
nanomaterials and the application of trace amounts of radiolabeled nanomaterials for
imaging and therapy of PC. The labeling of nanomaterials with radionuclides can be done
either extrinsically or intrinsically. In extrinsic method, the chelators bind to the surface of
nanomaterials while in intrinsic approach the radionuclides are inside the nano-sized
structure (Lee et al., 2015, Sun, Xu et al., 2007, Sun, Hoffman et al., 2012, Yang,
Sundaresan et al., 2013).

4.2.1

2.1. Nuclear imaging, therapy and theranostics

The use of radioisotopes is important in biomedical research, particularly in oncology. In
recent years, there has been increased uptake of the use of radionuclides for diagnostic and
therapeutic purposes (Abou, Pickett et al., 2015, Chatalic, Kwekkeboom et al., 2015, Shah,
Da Silva et al., 2015). By labeling the appropriate transport molecule with a therapeutic
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radionuclide that emits ionizing radiation such as beta-particle, alpha-particle, and Auger
electron emitters, it is possible to obtain internal irradiation at the cellular level following
the administration of radiopharmaceuticals. Similarly, by labeling the appropriate transport
molecule with a diagnostic radionuclide that emits ionizing radiation such as gamma or
positron emitters, it is possible to monitor tumor metabolism and proliferation at the
cellular level (Bailey & Humm, 2014, Saha, 2012, Ting, Chang et al., 2010, Zukotynski,
Jadvar et al., 2016). Table 1 summarizes the used therapeutic and theranostic radioisotopes
in combination with nanoscale particles for PC imaging and cancer therapy.
Table 4-1 Therapeutic and theranostic radioisotopes for PC imaging and cancer therapeutic
and theranostic.
Half-life

Emission type

Emax of α or β
(keV)

Therapeutic /
Theranostic

At

7.2 h

α

5870

Therapeutic

223

Ra

11.4 d

α

–

Therapeutic

224

Ra

3.6 d

α

–

Therapeutic

Ac

10.0 d

α

5830

Therapeutic

Isotope

211

225

186

Re

3.7 d

β¯, γ

1069

Theranostic

188

Re

17.0 h

β¯, γ

2120

Theranostic

2.7 d

β¯

2280

Therapeutic

14.3 d

β¯

1710

Therapeutic

I

8.0 d

β¯, γ

606

Theranostic

Ho

26.8 h

β¯, γ

1853

Theranostic

Cu

2.6 d

β¯, γ

580

Theranostic

2.7 d

β¯

960

Therapeutic

67 h

Auger, γ

420

Theranostic

90

Y

32

P

131

166

67

198

Au

111

In
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Interestingly, radionanomedicine utilizes the advantage of an huge surface to volume ratio
of nanomaterials by hydrophilization of nanomaterials, which offers production of multifunctional radiopharmaceuticals for both radionuclide therapy and hybrid imaging such as
PET/CT and PET/MRI (Lee, 2016, Lee et al., 2015). For instance, ‘Jeong’s method’ is one
of the most promising of producing functionally active multi-specific nanoparticles which
can make the most metallic or metal-oxide nanoparticles with hydrophobic surface to
hydrophilic and synthesizes an multifunction platform only in one step (Figure 4-1) (Choi,
Jeong et al., 2011, Kim, Kim et al., 2012, Lee, Jeong et al., 2012, Moon, Yang et al., 2016,
Yang, Moon et al., 2015).

Figure 4-1 The one-step method for multifunctional nanoparticle.
An schematic of Jeong’s one step method to generate an metallic or metal-oxide nanoparticles with
hydrophobic surface to hydrophilic and synthesizes an multifunction platform. Adopted with
permission (Choi et al., 2011, Kim et al., 2012, Yang et al., 2015).

Radiopharmaceuticals

including

18

F-fluorodeoxyglucose

(18F-FDG),

18

F-fluoro-5-

dihydrotestosterone (18F-FDHT) (Scher, Beer et al., 2010), 18F-fluorocholine (18F-FCH)
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(Caffo et al., 2014, De Giorgi, Caroli et al., 2015) and 68Ga-PSMA-11 (Afshar-Oromieh,
Avtzi et al., 2015a, Ebenhan, Vorster et al., 2015, Evans, Smith-Jones et al., 2011, Giesel,
Fiedler et al., 2015, Sterzing, Kratochwil et al., 2016) have been applied in the dose
optimization, evaluation of therapeutic pathways and assessment of therapeutic efficacy of
PC novel anticancer agents. In the following paragraphs we briefly overview the wellestablished radiopharmaceuticals for PC imaging and then will review the advantages and
challenges of the application of hybridization of nanomedicine technology with
radiochemistry.

4.2.2
18

PC Radiopharmaceuticals

F-FDHT is a radiolabeled analog of di-hydro-testosterone (DHT) which is the main ligand

for androgen receptor (AR) and it can be utilized for delineation and quantification of
locations where the AR is overexpressed (Vargas, Grimm et al., 2015). Pioneering efforts
by Larson et al. (Larson, Morris et al., 2004) and Dehdashti et al. (Dehdashti, Picus et al.,
2005) led to the establishment of 18F-FDHT as an alternative for the common 18F-FDGPET
scan. By virtue of 18F-FDGPET and 18F-FDHT PET scans, Fox et al. (Fox, Blanc et al.,
2009) categorized phenotypes of CRPC into three categories including AR Predominant
(lesions representing preferential accumulation on 18F-FDHT), Glycolysis Predominant
(lesions demonstrating preferential accumulation on

18

F-FDG), or AR/Glycolysis

Concordant (lesions showing preferential accumulation both 18F-FDGand 18F-FDHT in
agreement) (Castellucci & Jadvar, 2012, Vargas et al., 2015). Recently, it has been shown
that the intensity of 18F-FDHT uptake is meaningfully correlated with overall survival of
the patients (Vargas, Wassberg et al., 2014).
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Furthermore, higher glucose metabolism in malignant tissue in comparison with normal
tissue is known as a hallmark of cancer or as the Warburg effect (Gillies, Robey et al.,
2008). Besides, FDG is an analog of glucose which 18F-FDG can track in the glucose
metabolism of tissues and PET can visualize preferential accumulation of
malignant tissue. As a whole,

18

18

F-FDG in

F-FDG is the most common radiopharmaceutical in

oncology and nuclear medicine procedures (Jadvar, 2013b). However, as Jadvar (Jadvar,
2013a) extensively reviewed the utility and limitations of PET 18F-FDG, the helpfulness of
FDG PET in prostate cancer is still evolving and FDG PET cannot be favorable in detection
of prostate cancer in a relatively large portion of patients since FDG uptake in prostate
cancer is associated with the tumor differentiation level. However, the FDG PET scan still
could be a valuable method in the assessment of treatment response and in prediction of
patient outcome (Beauregard, Blouin et al., 2015).
Moreover, in contrast to the normal prostate cells, fatty acid synthesis plays a crucial role
in the rapid proliferation of prostate cancer cells since malignant cells need higher amounts
of fatty acid for their new membrane biogenesis (Suburu & Chen, 2012). Particularly,
choline is utilized for the biosynthesis of phosphatidylcholine and it is the basis for imaging
with 18F-FCH for the visualization of prostate cancer and bone, lymph nodes and visceral
metastasis (Apolo, Pandit-Taskar et al., 2008, Jadvar, 2013b). Currently, for staging and
monitoring treatment response, choline PET/CT using either 11C or 18F can be performed.
It is generally assumed that ADT does not significantly affect choline PET/CT uptake in
PC cells considering the biological mechanism of choline-based nuclear imaging
procedures (Choi et al., 2011, Kim et al., 2012, Lee et al., 2012, Moon et al., 2016, Yang
et al., 2015). However, a tendency of reduction in choline uptake following ADT is
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documented, particularly in hormone-naïve patients. Recent in vitro and in vivo evidence
indicates that prostate-specific membrane antigen (PSMA) is regulated by androgens and
suggests that ADT could considerably increase PSMA-ligand uptake. This means that for
those patients who are undergoing treatment with antiandrogens, evaluation of PSMA
targeted scans must account for this upregulation phenomenon. Therefore, the monitoring
of ADT response using choline PET/CT might be more reliable than PSMA-based imaging
(Bakht et al., 2016).

4.2.3

PSMA targeted radionuclide therapy

PSMA is a transmembrane protein that is over-expressed in more than 85% of primary
PC and its metastatic lesions in lymph nodes and bone (Ananias, van den Heuvel et al.,
2009, Minner, Wittmer et al., 2011, Rybalov, Ananias et al., 2014), hence representing a
promising target for imaging and therapy of PC. From a technical point of view, targeting
PSMA either by antibodies or by small molecules is feasible (Akhtar, Pail et al., 2011,
Lutje, Heskamp et al., 2015, Morigi, Stricker et al., 2015, Vargas et al., 2015). Particularly,
a new class of functional ligands including Glu-NH-CO-NH-Lys-[68Ga-(HBED-CC)]
or 68Ga-PSMA-11 (Afshar-Oromieh et al., 2015a, Ebenhan et al., 2015, Giesel et al., 2015,
Sterzing et al., 2016), PSMA-DKFZ-617 (Afshar-Oromieh, Hetzheim et al., 2015b, Delker,
Fendler et al., 2016, Kratochwil, Giesel et al., 2015a), 18F-DCFPyL (Szabo, Mena et al.,
2015) and EuK-Subkff-68Ga-DOTAGA (Herrmann, Bluemel et al., 2015) have proven
affinity to PSMA, and hence made possible the delineation of local PC and the possible
metastatic lesions. In addition, radio-metals such as 99mTc,
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In,

64

Cu,

86

Y, 68Ga

and 89Zr, have been employed for tracking PSMA due to their relative longer physical halflife in comparison with radio-halogens such as 18F, which is required for tracking PSMA
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(Banerjee, Pullambhatla et al., 2014). The available PSMA ligands can also be labeled
with therapeutic radionuclides such as lutetium-177 (Lutje et al., 2015).
It is expected that this new class of PSMA-binding radioligands can enhance the diagnosis
of recurrent PC and radionuclide therapy of PC (Freitag, Radtke et al., 2016). However,
the renal uptake of therapeutic PSMA targeted radiopharmaceuticals is a limiting factor
(Weineisen, Schottelius et al., 2015). The previously proposed solutions for decreasing offtarget radiation to the kidneys includes the application of the small-molecule PSMA
inhibitor comedication (Kratochwil, Giesel et al., 2015b), the employment of polyethylene
glycol (PEG) polymer chains (Wilbur, Chyan et al., 2012) and the use of the nanoparticlebased platforms (Behnam Azad, Banerjee et al., 2015b, Moon, Yang et al.).
Albumin-based platforms
Albumin is the most abundant protein in blood plasma and human serum albumin (HSA)
has appeared as a multipurpose carrier in nanomedicine, particularly for treating diabetes
and targeting cancer, enhancing the pharmacokinetic profile of delivering therapeutic or
diagnostic agents to the malignant tissues (Elsadek & Kratz, 2012, Loureiro, G Azoia et
al., 2016, Zhao, Wang et al., 2016). Banerjee et al. (Banerjee, Wang et al., 2014) suggested
an albumin-based nanoformulation for PSMA by covalent conjugation of fluorescein for
PC cell imaging which DTPA used for
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In-labeling for SPECT, Glu-Lys urea used for

PSMA targeting and NIR dye 800 CW played the role of in vivo optical imaging probe. In
addition, Moon et al. (Moon et al., 2016) developed a nanoparticle-based PET/MR dualmodal imaging probe for targeting PSMA with lower kidney uptake. Figure 2B represents
the recently proposed PSMA radioligand platforms for targeting PC using Jeong’s method
(Choi et al., 2011, Kim et al., 2012, Lee et al., 2012, Moon et al., 2016, Yang et al., 2015).
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4.2.4

Radioactive gold nanoparticles

Chanda et al. (Chanda, Kan et al., 2010) reported on PC therapy using glycoprotein
functionalized gold nanoparticles containing radioactive β-emitting Au-198. Intratumoral
administration of a single dose of their suggested platform (70 Gy) caused significant tumor
regression and effective control in the growth of PC over 30 days. In addition, Shukla et al.
(Shukla, Chanda et al., 2012) also employed prostate tumor specific epigallocatechingallate (EGCg) functionalized radioactive β-emitting Au-198. They reported an 80%
reduction of PC-3 xenograft tumor volumes after 28 days intratumoral administration of
198

Au-nanoparticle-EGCg.

4.2.5

Nano-sized peptides

Nano-sized peptides are an appealing candidate for peptide receptor radiotherapy (PRRT)
of PC. The gastrin-releasing peptide receptor (GRPR) has been revealed to be
overexpressed in a wide variety of cancer cells including PC. Bombesin is a nano-sized
neuropeptide with high affinity toward GRPR (de Jong, Breeman et al., 2009, Durkan,
Lambrecht et al., 2007, Emonds, Swinnen et al., 2009, Mendoza-Sanchez, Ferro-Flores et
al., 2010). Therefore, many research groups used radiolabel bombesin for evaluation of its
potential for PC therapy and imaging of metastatic areas (Hoffman, Gali et al., 2003, Liu,
Yan et al., 2009, Scopinaro, De Vincentis et al., 2003). For instance, Faintuch et al.
(Faintuch, Núñez et al., 2011) using

99m

Tc and nano-sized bombesin showed that a pre-

targeting approach with a peptide could be promising for PC therapy. Lim et al. (Lim, Cho
et al., 2015a, Lim et al., 2015b) studied the feasibility of application of a radiolabeled
bombesin compound via

177

Lu to prepare radiolabeled candidates for the treatment of

GRPR-expressing prostate tumors. Also, a multifunctional system of
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99m

Tc labelled gold

nanoparticles conjugated to bombesin has been suggested for PC PRRT (Mendoza-Sanchez
et al., 2010). The in vivo SPECT/CT images in mice presented a considerable uptake in
PC3 xenograft. Lastly, Roivainen et al. (Roivainen, Kahkonen et al., 2013) reposted the
first human study for evaluation of the safety, tolerability, metabolism, pharmacokinetics,
biodistribution, and radiation dosimetry of a 68Ga-bombesin compound.
Further, atrial natriuretic peptide has been detected to have anticancer properties by
interaction with the cancer cell surface natriuretic peptide receptor A (NPRA) and
natriuretic peptide clearance receptor (NPRC). Pressly et al. (Pressly, Pierce et al., 2013)
designed an amphiphilic comb-like radiolabeled nanoparticle with controlled properties
through modular construction containing C-atrial natriuretic factor (CANF). PET imaging
with a

64

Cu-CANF-Comb in a PC xenograft tumor model presented high blood pool

retention, low renal clearance, enhanced tumor uptake, and decreased hepatic burden
relative to the non-targeted 64Cu-Comb.

4.2.6

Nano-sized polymers and liposomes

Porphysomes, which were pioneered by Dr. Zheng’s group, are formed by the selfassembly of ‘porpholipids’ into spherical nanostructures (Figure 4-2A) (Jin & Zheng, 2011,
Lovell, Jin et al., 2011, Valic & Zheng, 2016). This group validated in vivo application of
64

Cu-porphysomes in an orthotopic PC and bony metastatic PC animal models. They also

displayed a multimodal delineation of orthotopic tumors on both the macro- and the
microscopic scales using both PET and fluorescence. Also, the nano-sized Poly(APMA)DOTA polymer conjugated with a therapeutic β-emitter copper isotope, such as 67Cu has
been also suggested for PC therapy (Yuan, You et al., 2006).
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A

B

Figure 4-2 Proposed nan-platforms for application in PC radionanomedicine
(A) future potential of porphysomes. Adopted with permission (Liu et al., 2013) (B) future potential
of dendrimers. Adopted with permission (Lo, Kumar et al., 2013) .

4.2.7

X-ray CT imaging

The sensitivity of X-ray CT conventionally can be enhanced by small iodinated compounds
as injectable contrast agents. However, the iodinated contrast agents have some limiting
factors such as fast renal clearance and short circulation times. Moreover, the X-ray
attenuation of iodine is not effective for clinical CT that requires high-energy X-ray. To
overcome these challenges, nano-sized iodinated CT contrast agents nanoparticles with
heavy atoms including gold, lanthanides, and tantalum might be used as more effective
contrast agents (Lee, Choi et al., 2013). In particular, a greater attenuation of gold
nanoparticles at both of low and high X-ray energies reported (Jackson, Rahman et al.,
2010, Popovtzer, Agrawal et al., 2008). For instance, Kim et al. (Kim, Jeong et al., 2010)
developed a multifunctional nanoparticle as X-ray CT constant agent and PSMA-targeted
delivery of doxorubicin for PC theranostic. The suggested gold nanoplatform displayed up
to more than 4-fold greater CT intensity for a LNCaP cell line as a PSMA positive PC cell
line than that of a PC-3 cell line as a PSMA negative PC cell. Furthermore, Bacteriolytic
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therapy using the anaerobic bacterium Clostridium novyi-NT has been proposed as a
promising approach for the treatment of solid tumors such as PC (Diaz, Cheong et al.,
2005). Recently, Park et al. (Park, Cho et al., 2016) labeled C. novyi-NT spores with gold
nanoparticles for X-ray CT imaging of spore delivery to PC tumor after intratumoral
injection to PC-3 cell line xenograft model.

4.2.8

Optical imaging and hyperthermia

While optical imaging and hyperthermia cannot be classified as radiotherapeutic
approaches, by the virtue of multifunctionality and surface modification abilities of
nanoparticles we can combine them with radiation-based modalities to enhance PC therapy.
For example, during development of a nanoplatform for hyperthermia, radiolabeling
technology can visualize the biodistribution and the specific organ uptake of nanoparticles
(Cui, Han et al., 2009). In addition, the comparison of optical signals with nuclear
emissions from multifunctional nanoparticles is a potent approach for confirmation of
delineated areas by either optical signals or nuclear emissions (Hu, Wang et al., 2015).
Below we briefly summarize the frequently used nanoparticles in optical imaging and
hyperthermia in PC considering their potential for combination with radiation technology.
Quantum dots
Quantum dots (QD) can have the dual role of energy donors and acceptors because of their
fluorescence resonance energy transfer capability; hence, QD in combination with
photosensitizing agents have the potential for application in photodynamic therapy. After
exposure to ionizing radiation such as X-rays, heavy nanoscale particles emit scintillation
as well as persistent luminescence or Auger electrons. Ionizing radiation (e.g., X-rays and
gamma rays) penetrates much more profoundly than non-ionizing radiations such as UV
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(Bakht et al., 2012, Kamila, McEwan et al., 2016, Yaghini, Seifalian et al., 2009). The
cytotoxicity of QDs is also a crucial issue and in a meta-analyses, Oh et al. (Oh, Liu et al.,
2016) show that toxicity is closely correlated with QD surface properties (including shell,
ligand and surface modifications), diameter, assay type and exposure time.
Moreover, QD-antibody conjugates are developing for immunoassays against prostate
specific antigen (PSA). Additionally, the photophysical and nanometric properties of QDs
are attractive for their application in Förster resonance energy transfer (FRET) of PSA
(Bhuckory, Lefebvre et al., 2016, Brazhnik, Sokolova et al., 2015, Gao, Zhang et al., 2012,
Garcia-Cortes, Encinar et al., 2016, Gokarna, Jin et al., 2008, Hu, Chu et al., 2011, Jin,
Li et al., 2012, Kwon, Lee et al., 2013, Leung, 2004a, Leung, 2004b, Li, Li et al., 2014, Lin,
Liu et al., 2015, Lin, Ma et al., 2014b, Malic, Sandros et al., 2011, Mitani, Harada et al.,
2014, Pei, Zhu et al., 2015, Ruan, Yu et al., 2011, Singh, Singh et al., 2012, Walker, Morgan
et al., 2012, Wu, Liu et al., 2016, Yeh, Hsiao et al., 2016, Zhang, Hubbard et al., 2013,
Zhang, Dai et al., 2013). For instance, Cui et al. (Cui et al., 2009) reported conjugation of
fluorescent magnetic nanoparticles with a single chain Fv antibody against γseminoprotein for PC theranostic. The proposed platform displayed highly specific
targeting, fluorescent imaging and MR imaging, and selective anticancer impact on the PC
xenografts. Recently, a dual receptor–targeting dual-modality PET/Near-infrared
fluorescence (NIRF) probe was proposed by Hu et al. (Hu et al., 2015) for assessment of
the pharmacokinetics PC using QDs. They demonstrated that their dual-function
PET/NIRF imaging is able to evaluate the biodistribution and PC tumor-targeting efficacy
of the 18F-labeled functionalized QDs.
Carbon nanotubes
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The characteristics of carbon nanotubes (CNTs) can be applied for photodynamic or
photothermal irradiation therapy of targeted tumor cells. In addition, CNTs in either singlewalled carbon nanotubes (SWCNT) or multi-walled carbon nanotube (MWCNT)
formations powerfully absorb Near-infrared (NIR) radiation and convert absorbed energy
to released heat (Hassan, Smyth et al., 2016, Newland, Thomas et al., 2016, Rodrigues,
Leite et al., 2016, Wailes & Levi-Polyachenko, 2016). It should be noted that the long-term
application of CNP may be associated with cancer risk (Lacerda, Bianco et al., 2006,
Marchesan, Kostarelos et al., 2015). On the other hand, MWCNT-based field-effect
transistors have been widely evaluated due to their applications to electric circuit and biosensing chips. Initially, Li et al. (Li, Curreli et al., 2005) proposed complementary
detection of PSA as a potent PC biomarker using In2O3 nanowires and CNTs. In this work,
a combination of In2O3 nanowires and MWCNTs for the detection of PSA has been used.
Consequently, many other research groups have developed more advanced CNT-based
sensors for measurement of electrochemical impedance, detection of PSA other PC
biomarkers such as osteopontin (Briman, Artukovic et al., 2007, Chikkaveeraiah, Bhirde et
al., 2009, Kim, Lee et al., 2009, Krishnan, Diagaradjane et al., 2010, Lerner, D'Souza et
al., 2012, Okuno, Maehashi et al., 2007, Panini, Messina et al., 2008, Patra, Roy et al.,
2015, Pei et al., 2015, Salimi, Kavosi et al., 2013, Sharma, Hong et al., 2015, Silva, Lima
et al., 2016, Tian, Zhao et al., 2012, Tran, Piro et al., 2013, YeoHeung, Zhongyun et al.,
2007). Moreover, Tran et al. (Tran et al., 2013) suggested a label-free microRNA-141
sensor based on an interpenetrated network of CNTs and electroactive polymer.
Magnetic nanoparticle
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Banerjee et al. (Banerjee, Pullambhatla et al., 2011) evaluated the feasibility of sequential
SPECT and optical imaging of PC. Following this publication, Behnam et al. (Behnam
Azad, Banerjee et al., 2015a) proposed a PSMA-targeted bionized nanoferrite (BNF)
nanoparticle and its biological evaluation in a PC animal model. The BNF fluorescent
magnetic nanoparticle formulation displayed proper targeting specificity. They also
confirmed the biodistribution of their suggested platform by SPECT imaging.
Consequently, Chen et al. (Chen, Penet et al., 2012) have developed a theranostic PSMAtargeted nanoplex platform for delivery of small interfering RNA (siRNA) along with a
prodrug enzyme to PC xenografts. Down-regulation of the candidate siRNA target, choline
kinase, and the conversion of the nontoxic prodrug 5-fluorocytosine (5-FC) to cytotoxic 5fluorouracil (5-FU) were also visualized with noninvasive imaging. Interestingly, the
proposed platform was well-tolerated and a low renal uptake was observed. Huang and Liu
(Huang & Liu, 2015) have also proposed polymer nanostructures for simultaneous
multiphoton imaging and chemo-photothermal therapy of PC.
Wang et al. (Wang, Sefah et al., 2013) evaluated aptamers selected against DU145 CRPC
cell line and their subpopulation of cancer stem cells were linked to the surfaces of gold
nanorods and the resulting conjugates were utilized to target both cancer cells and cancer
stem cells by NIR laser irradiation. Lu et al. (Lu, Singh et al., 2010) subsequently suggested
a multifunctional gold nano-popcorn-based surface-enhanced Raman scattering (SERS)
assay for simultaneous imaging and photothermal therapy of PC. They presented that
multifunctional popcorn-shaped gold nanoparticles form several hot spots and provide a
substantial improvement of the Raman signal intensity.
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Buckway et al. (Buckway, Frazier et al., 2014) proposed that PC therapy using a
therapeutic 90Y labeled N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer can be
improved with localized tumor hyperthermia. Additionally, an
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In labeled HPMA

copolymer system for SPECT was utilized to monitor the biodistribution and tumor
reduction as a result of hyperthermia. They reported considerable shrinkage of tumor size
in the hyperthermia treated tumors with 90Y-HPMA copolymer conjugates in comparison
with single modality PC treatments.
Dendrimers
Dendrimers have discrete highly compact nano-sized structures with successive branched
layers and multivalent functional end groups. These exceptional characteristics have made
dendrimers appealing for drug delivery and radionanomedicine applications as
nanoscaffold systems (Glasgow & Chougule, 2015, Sharma & Kakkar, 2015, Sharma,
Maheshwari et al., 2015, Sk & Kojima, 2015, Yang, 2016). Lo et al. (Lo et al., 2013)
reviewed and discussed the reported approaches of using dendrimer nanoscaffolds for PC
radionanomedicine (Figure 4-2B).

4.2.9

MRI

MRI is a diagnostic modality extensively used in clinics to scrutinize the anatomical
structures of the body and also provide some physiological data. The main advantage of
MRI is the high level of spatial resolution of tissues, particularly soft tissues such as
prostate, as compared to other imaging modalities. Furthermore, in contrast to nuclear
medicine modalities including PET and SPECT, MRI does not utilize ionizing radiation
for imaging (Khan & Gibbons, 2014, Mayles et al., 2007). The applications of MRI for PC
diagnostics are not limited to initial diagnosis, but also have an emerging role in MRI119

guided biopsy and in active surveillance, surgery staging and treatment planning
(Czarniecki, Jakucinski et al., 2016).
It should be highlighted that the sensitivity of MRI for molecular imaging is not appealing
when relying solely on endogenous contrast of tissues. Magnetic nanoparticles, particularly
superparamagnetic iron oxide nanoparticles (SPIONs), have long been considered as MRI
contrast agents (Xie, Liu et al., 2011). Many research groups have developed nanoparticlebased contrast agents such as cobalt zinc ferrite nanoparticles (You, Lee et al., 2015),
magnetic nanobeads (Pablico-Lansigan, Hickling et al., 2013), paramagnetic gadoliniumbased nanoparticle (Goswami, Ma et al., 2013), for improving PC diagnostics by MRI.
The combination of either PET or SPECT with MRI modalities into a single hybrid
functional and anatomic modality has been confirmed to synergistically compensate the
limitations of each modality. This has the potential to improve diagnostic accuracy and
advance the progress of therapeutics. To take advantage of the progress of the fused
PET/MRI or SPECT/MRI, nanoparticle-based agents are being developed for multimodal
applications (Garcia, Tang et al., 2015). Thoreck et al. (Thorek, Ulmert et al., 2014)
reported a multimodal nanoparticle, 89Zr-ferumoxytol, for the advanced detection of lymph
nodes using fused PET/MRI. As part of their study, they could delineate local and extended
lymphatic transport in a transgenic model of PC by their PET/MRI agent. In addition, in a
very recent study, Moon et al. (Moon et al., 2016) reported the specific PSMA-targeting
iron oxide nanoparticle, DOTA-IO-GUL, as a dual-modality probe for complementary
PET/MR imaging (Figure 4-3).
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A

B

Figure 4-3 An PSMA radionanomedicine platform for targeted PC molecular imaging and
therapy.
(A) A diagram of encapsulated multifunctional DOTA-IO-GUL. (B) PSMA-selective uptake
result in micro PET imaging. Adopted with permission (Moon et al., 2016).

4.2.10 External beam radiation therapy
A nanoparticle-induced dose enhancement effect has been developed to enhance the
therapeutic effectiveness of ionizing radiation in external beam radiotherapy. Application
of tumor-specific nanoscale agents in external beam radiation therapy aims to increase the
specificity of radiation therapy and decrease toxicity to normal tissues (Bakht et al., 2012).
In particular, the application of nanoparticles as radiosensitizers is a fast growing field
(Babaei & Ganjalikhani, 2014, Rahman, Corde et al., 2014, Smith, Ackerly et al., 2015).
Sensitizers in PC radiotherapy have included gold nanoparticles (Rahman, Bishara et al.,
2009, Zhang, Xing et al., 2008), magnetic nanoparticles (Johannsen, Thiesen et al., 2006),
yttrium oxide nanoscintillators (Scaffidi, Gregas et al., 2011) and superparamagnetic zinc
ferrite spinel (ZnFe2O4) (Butterworth, McMahon et al., 2013, Coulter, Butterworth et al.,
2015, Hidayatullah, Nurhasanah et al., 2016, Meidanchi, Akhavan et al., 2015a).
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Roa et al. (Roa, Zhang et al., 2009a) found that glucose-capped gold nanoparticles improve
radiation sensitivity in radiation-resistant human PC cells by altering cell cycle regulation
via sensitizing cells to a G1/S cell cycle arrest followed by apoptosis. Yao et al. (Yao, Qiu
et al.) used two different PC cell lines, PC-3 and 22Rv1 to test the effects of a novel DNA
damage repair inhibitor, Dbait nanoparticle, on radiosensitization. Using in vivo xenograft
models they found that Dbait considerably decreased tumor growth by the accumulation of
DNA double strand breaks. In addition, Meidanchi et al. (Meidanchi, Akhavan et al., 2015b)
used ZnFe2O4 as a radiosensitizer in vitro using xenographs of the LNCaP cell line and
gamma irradiation with a 60Co source. In the presence of ZnFe2O4 nanoparticles, cells were
17 times more sensitive to gamma irradiation.
Among the currently studied nanoparticles, gold and bismuth-based nanostructures are
promising candidates for enhancing sensitivity to external beam radiation (Alqathami,
Blencowe et al., 2016). Table 4-2 presents a list of PC in vitro studies evaluating the
radiosensitizing properties of nanoparticles. Bismuth sulfide (Bi2S3)-NPs have been
examined as a more cost effective radiosensitizer for external beam radiation therapy in PC
(Algethami, Geso et al., 2015). The higher enhancement of external beam radiation therapy
capability of Bi2S3 rather than gold nanoparticles could be due to the fact that bismuth has
a higher high atomic number (Z) than gold, causing a higher the photoelectric effect. In
addition, bismuth has a higher density of free electrons than gold, which leads to increased
probability of Compton scattering. In all, nanoparticle biocompatibility, biodistribution and
uptake should be comprehensively investigated to choose the best option among the wide
range of possible systems for enhancement of external beam radiation therapy.
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Table 4-2 Overview of in vitro experiment using PC representing the radiosensitizing
properties of nanostructures.
Reference

Type of
radiosensitizer

Partic
le size
(nm)

Surface
coating
compound

Concentration

Radiation
Source
energy

PC Cell
line
model

Sensitizer
enhancement

Butterworth et al.
(Butterworth,
Coulter et al.,
2010)

Au NP

1.9

Thiol

2.4 µM and 0.24
µM

160 kVp

DU-145
PC-3

<1
<1.07

Coulter et al.
(Coulter, Jain et
al., 2012)

Au NP

1.9

Thiol

12 µM

160 kVp

DU-145

<1.8

1.9

Thiol

12 µM

160 kVp
6 MV
15 MV
6 MeV e16 MeV
e-

DU-145

<1.41
<1.29
1.16
<1.12
1.35

Jain et al. (Jain,
Coulter et al.,
2011)

Roa et al. (Roa,
Zhang et al.,
2009b)

Au NP

10.8

thioglucose

15 nM

662 keV

DU-145

>1.5

Zhang et
al.(Zhang et al.,
2008)

Au

30

thioglucose

15 nM

200 kVp

DU-145

>1.3

Wolfe et al.
(Wolfe, Chatterjee
et al., 2015)

Au NP

31 x 9

polyethylen
e glycol

0.1 μM
40 μM

6 MV

PC-3

1.35

Yao et al. (Yao et
al.)

Dbait

170

H1 polymer

1 μg/1 mL

9 Gy

PC-3
22Rv1

1.64
1.43

Algethami et al.
(Algethami et al.,
2015)

Au NP

1.9

tetraethylen
e glycol

0.5 mM
1.0 mM

80KVp

PC-3

1.45
2.65

Bi2S3 NP

3-5

polyvinylpy
rrolidone

0.5 mM
1.0 mM

80KVp

PC-3

1.6
3.07

4.2.11 Nanoparticle-based brachytherapy
Brachytherapy is the temporary or permanent implantation of small radioactive sources
directly within malignant tissues such as PC. It is one of the highly effective techniques for
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the delivery of larger radiation doses in a few number of treatment sections (Khan &
Gibbons, 2014). In particular, the radiobiological nature of PC cells represent a low
alpha/beta ratio, hence hypofractionation of radiation could lead to the best chance of PC
radiation therapy (Cabrera & Lee, 2013, Sanfilippo & Cooper, 2014). Brachytherapy offers
considerable benefits to PC treatment including proximity of the radiation source to the PC
tissue and the rapid dose fall-off beyond the edge of the prostate which prevent toxicity of
surrounding tissue. However, recent clinical evidence indicates that dose conformity and
targeting accuracy present challenges for conventional brachytherapy which can lead to
adverse side effects for the patients (Helou, Morton et al., 2014, Morris, Tyldesley et al.,
2015, Tselis, Tunn et al., 2013). Application of multiparametric MRI to better identify and
localize intraprostatic tumors with simultaneous use of nanomolecular radiosensitizers
such as gold nanoparticles may enhance doses to PC tissue without the requisite hazard of
increased side effects of brachytherapy (Nicolae, Venugopal et al., 2016). Ngwa et al.
(Ngwa, Korideck et al., 2013) was among the first to present experimental evidence that
gold nanoparticles can be used for radiosensitization of brachytherapy. Using γH2AX foci
to quantify damaged DNA after brachytherapy with or without gold nanoparticles, this
group found that the presence of nanoparticles enhanced DNA damage by 70 to 130%.
Despite the promise of sensitizing brachytherapy with nanoparticles in vitro, the delivery
of effective concentrations of nanoparticles into a solid tumor such as PC by systematic
injection of nanoparticles is a limiting factor in oncology (Jain & Stylianopoulos, 2010).
To overcome this technical problem, Sinha et al. (Sinha, Cifter et al., 2015) suggested that
sustained concentrations of gold nanoparticles could be achieved in PC if they were loaded
into routinely used brachytherapy spacers for in situ release into the source. Testing this
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theory they found that changing the size of gold nanolattices can enhance dose to tumor
voxels and subvolumes. Similarly, Kumar et al. (Kumar, Belz et al., 2015) produced
implantable brachytherapy spacers loaded with silica nanoparticles conjugated to
chemotherapy agents and demonstrated a potential to sensitize chemoradiation therapy.
Attempts have been made to replace the source of radiation with compact low-energy Xray generating devices and to develop different approaches of radiation delivery to tumors.
Magnetite nanoparticles for nonradionuclide brachytherapy are also under consideration to
construct an X-ray tube small enough to be implanted in or near the tumor (Liu, Sozontov
et al., 2010, Safronov, Sozontov et al., 2015). The reported dose enhancements using
nanoparticle-based brachytherapy are mainly due to the augmented photoelectron and
characteristic X–ray production from the radiosensitizer nanoparticles such as gold
nanoparticles. In addition, the Auger electrons escaping from the nanoparticles also can
play role in dose enhancement. These radiations from nanoparticles may cause biological
damage at cellular and sub–cellular level proportional with the biological distribution of
nanoparticles within the PC cells (Amato, Italiano et al., 2013).
4.3

NANOTECHNOLOGY-BASED STUDY OF PC BIOLOGY

Androgen receptor (AR) signaling can be reactivated in several ways to result in more
aggressive and difficult to treat CRPC. Known mechanisms of CRPC development include
(i) AR overexpression, (ii) AR splice variants (Antonarakis, Lu et al., 2014) (iii) mutations
arising in the AR such as ARF876L leading to enhanced ligand response (Korpal, Korn et al.,
2013), (iv) crosstalk with other signaling pathways (Kaarbø, Klokk et al., 2007, Wong,
Ferraldeschi et al., 2014) and (v) altered expression of transcriptional coactivators thereby
improving AR transactivation and (vi) the emergence of prostate cancer stem-like cells
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(Chesire, Ewing et al., 2000, Debes & Tindall, 2004, Mitani et al., 2014, Mitani et al., 2011,
Schaufele, Carbonell et al., 2005). It has been reported that knocking down the expression
of the AR gene by a siRNA-based approach can cause cell death via apoptosis. Yang et al.
(Yang, Xie et al., 2012) utilized a biodegradable nanocarrier to deliver short interfering
RNA (siRNA) against the AR in PC cells. Similarly, Wang et al. (Wang, Zhang et al., 2014)
developed nanobubbles carrying AR siRNA could be possibly used as gene vectors
accompanied by ultrasonic irradiation for the treatment of CRPC.
Nanoparticle-facilitated siRNA delivery provides a potential tool for loss-of-function
evaluation of genes such as wild type AR, AR splice variants and mutated ARs in the PC
models. It is anticipated that radionanomedicine can play crucial role in expanding our
knowledge about targeting AR using nanocarrier-based approaches for siRNA delivery due
to the importance of visualization of tumor alterations after knocking down the expression
of the potential genes.
Such as many other cancers, CRPC is highly heterogeneous (Brocks, Assenov et al., 2014b,
Zhang, Meng et al., 2015). Most early-stage tumours are composed of cells positive for
PSA and AR, while advanced and metastatic PC evolves to be primarily composed of
poorly differentiated cells lacking PSA or AR (Li, Chen et al., 2008, Patrawala, CalhounDavis et al., 2007, Qin, Liu et al., 2012). PC stem cells are capable of giving rise to a
heterogenous tumour and are highly resistant to known therapies (Laffin & Tang, 2010).
PC stem cells are capable of driving relapse, metastasis and therapy resistance and hence
identification of this population is an area of high importance. Liu et al. (Liu, Lau et al.,
2010) used multiplexed QDs and wavelength-resolved spectral imaging for molecular
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mapping of tumor heterogeneity on human PC tissue specimens. Hence the use of
nanoparticles can aid in the targeting of cells within a heterogeneous environment.

4.3.1

Potential of exosomes in PC theranostic

Exosomes are enriched in bioactive molecules including RNA, miRNAs and proteins (Liu,
Hsieh et al., 2016, Srivastava, Babu et al., 2016, Thind & Wilson, 2016, Wendler,
Favicchio et al., 2016, Zhang, Pei et al., 2016). It has been confirmed that tumor derived
exosomes shuttle RNA, miRNAs and proteins to cells within the tumor environment to
suppress the immune response, accelerate tumor proliferation and facilitate metastasis
(Keller, König et al., 2009). Exosomal proteins, mRNA and miRNAs can cause alteration
in metabolism and function of PC cells. In addition, they can function as potent biomarkers
for diagnosis and prognosis.
Tumor-derived exosomes may pave the way for formation of a protumorigenic niche and
may direct progenitor cells (Quail & Joyce, 2013). For instance, exosomes derived from
metastatic melanoma cells amplified the growth and metastasis of primary tumors (Peinado,
Alečković et al., 2012). PC exosomes can drive the malignancy to expand to adjacent
normal tissues and sensitize other sites to form a pro-tumorigenic lesion. PC exosomes can
be isolated via different sources including serum and urine of PC patients. Rauschenberger
et al. (Rauschenberger, Staar et al., 2016) demonstrated that exosomes secreted by PC
cells can inhibit the viability of adjacent cells via exosome communication to improve the
ability of PC cell progression and support the expansion ability. A recent study presented
that PTEN carried by exosomes in the tumor microenvironment can compensate for PTEN
loss in PC cells, while exosomes found in benign prostate do not carry PTEN (Gabriel,
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Ingram et al., 2013). Thus, it is speculated the early stage PC could be managed by
supplying exosomes containing tumor-suppressor proteins (Figure 4-4).

Tumor promoter exosomes

Pre-metastatic
niche creation

Serum of PC patients

Urine of PC patients

ITGA3, ITGB1
PSA, PSMA
δ-catenin
miR-574-3p, miR-141-5p, miR-21-5p
miR-483-5p
PCA3 (ncRNA), ERG (mRNA)
AGR2 SV-G, AGR2 SV-H (mRNA)

NEU3
CYP17A1
HSP72
Survivin
CML28
PTEN
miR-375, miR-574, miR-21
miR-141
miR-1290
lincRNA-p21 (ncRNA)

Figure 4-4 A schematic of the tumor promoting impact of PC exosome on prostate benign
cells and creation of pre-metastatic niche as a result of circulation of PC exosomes in body.
List of exosome specific RNAs and proteins in PC based on isolation source are also presented.
Some elements of this figure were produced using Servier Medical Art image bank
(www.servier.com).

Radioexosomic is an emerging subcategory of radionanomedicine and many research
groups are currently developing radiochemical protocols for the radiolabeling of exosomes.
Radiolabeling exosomes will allow researchers and clinicians to visualize exosome
distribution in vivo and estimate pre-metastatic niches (Hwang do, Choi et al., 2015, Jung,
Youn et al., 2015a, Jung, Kim et al., 2015, Nikolopoulou, Amor-Coarasa et al., 2016). Jung
et al. (Jung, Youn et al., 2015b) isolated exosomes from mouse breast cancer cells and
radiolabeled them with 64Cu for PET imaging. Nikolopoulou et al. (Nikolopoulou et al.,
2016) isolated exosomes from highly metastatic lung-tropic breast cancer cells and
radiolabeld them by 131I. Interestingly, 131I-exosomes imaging represented a fast blood and
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background tissue clearance with specific uptake in the lungs, one of the primary locations
for PC metastasis. It is predicted that the study of PC exosomes, and the resolution of
biodistribution using radioexosomic tracing technology, could expand our knowledge
about PC biology. Noninvasive imaging of PC exosomes by fluorescence labeling (Tian,
Zhu et al., 2013), bioluminescence reporter system (Lai, Mardini et al., 2014),
radionuclide-based imaging (Hwang do et al., 2015, Morishita, Takahashi et al., 2015) and
MRI (De La Pena, Madrigal et al., 2009, Hu, Wickline et al., 2014) are feasible and could
provide visualization of the biodistribution of PC exosomes. This is reviewed by Choi and
Lee (Choi & Lee, 2016)and we have provided an illustruation of potential strategies for
visualization of exosomes (Fig. 5).
Lipophilic Fluorescence Dye
(PKH, DiR or DiI)

Reporter Protein
Fluorescence (e.g. GFP – CD63)
Bioluminescence (e.g. gLuc – lactadherin)

Fluorescence dye

T
M

Extracellular
Vesicle

Radionuclide Trapping
(99mTc-HMPAO, 111In-oxine)

Iron Oxide Nanoparticle Trapping
(For magnetic resonance imaging)

Figure 4-5 Radioesosomic strategies for visualization of exosomes (Choi & Lee, 2016).
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4.4

CONCLUSION

Nanoscale particles are constantly evolving for their potential uses as tools in nuclear
medicine. This includes artificial nanostructures such as QDs, magnetite nanoparticles,
CNTs, dendrimers, gold nanoparticles and nano-sized peptides as well as natural
nanostructures such as secreted nano-sized extracellular vesicles (exosomes).
Radionanomedicine is a hybrid term for the coincident application of radiation technology
and nanomedicine. Radioexosomics use radiation technology and nuclear tracing
technology to study exosome functions, cytotoxicity, cancerogenicity, and biodistribution.
There are currently many exciting implications for the use of radionanomedicine in the
imaging and therapy of PC. Nanomaterials have properties that render them a feasible
option in producing multi-functional radiopharmaceuticals used both in radionuclide
therapy as well as in hybrid imaging such as PET/CT and PET/MRI. This review
summarized some of the cutting edge uses for nanoparticles such as enhancing the
sensitivity of MRI and external beam radiation as valuable approaches in the treatment of
PC. The ability of nanoparticles to target specific principles of PC biology make them an
attractive candidate for personalized medicine.
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5.1 PSMA-SUPPRESSION IN NEPC
Mannweiler et al. reported that a direct correlation between histological parameters and
PSMA could not be established; specifically in AdPC patients with distant metastasis
(Mannweiler, Amersdorfer et al., 2009). In this study, we report the possibility of PSMA
suppression in high grades of CRPC. We further show that expression of the PSMA gene,
FOLH1, inversely correlates with markers of NE differentiation. This data supports
previous clinical reports showing a suppression of PSMA-targeted nuclear scans for NEPC
patients (Chakraborty et al., 2015, Tosoian et al., 2017a, Usmani et al., 2017). This mounts
the possibility that portions of AdPC patients undergoing ARPI will transdifferentiate to
NEPC

and

will

subsequently

fail

to

adequately

uptake

PSMA-targeted

radiopharmaceuticals.
In vitro modeling of NE-differentiation of PC as a result of hormonal therapy by CSS-FBS
treatment of LNCaP cell line has been extensively studied (Nouri, Caradec et al., 2017,
Sang, Hulsurkar et al., 2016, Zhang, Zheng et al., 2018). Mechanistically, Zang et al.
(Zhang, Kondrikov et al., 2003) demonstrated CSS-FBS treatment activates MEK-ERK
pathway and inhibition of MEK prevents NE-differentiation under CSS-FBS. Also, their
work and many other studies demonstrated the in vitro nerite formation in LNCaP cell line
could be associated with the expression of NSE as a NE-marker. Chang et al. (Chang,
Wang et al., 2014) quantified the formed neurite lengths and displayed neurite lengths are
proportional with the protein levels of AR. Or work demonstrated the suppression of
PSMA in this previously proposed in vitro model of NEPC.
Clinical reports show the possibility of a false-positive uptake of PSMA-targeted
radioligand after ARPI (Hope, Truillet et al., 2017) and a false-negative uptake of this
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radioligand in NEPC (Chakraborty et al., 2015, Tosoian et al., 2017a, Usmani et al., 2017).
We previously reviewed the available preclinical evidence justifying molecular
backgrounds of a false-positive uptake of PSMA-targeted radioligand after ARPI (Bakht,
Oh et al., 2017b). However, there is a lack of preclinical evidence for the reported falsenegative uptake of PSMA-targeted radioligand. The observed significant suppression of
FOLH1 expression in PDX models shown in this work are the first preclinical evidence
validating false-negative uptake of PSMA-targeted radioligand in NEPC. The suggested
second model of alteration of PSMA on Figure 2-12E best describes the progression of
AdPC patients undergoing ARPI whom end up with NEPC.
There is literature to support that SSTR-targeted radioligands such as

68

Ga-

DOTATOC or 68Ga-DOTATATE could be valuable alternatives for PSMA-negative and
non-hormone naïve patients. Usmani et al. compared 68Ga-PSMA versus 68Ga-DOTA NOC
PET-CT in a 62-year old NEPC patient and reported that the NEPC tumor and its metastatic
lesions have avid uptake of

68

Ga-DOTA NOC while the PSMA uptake was faint and

inconclusive (Usmani et al., 2017). Additionally, in a study on 12 patients with CRPC,
68

Ga-DOTA-TATE PET/CT is suggested for NEPC imaging and early detection of

metastatic lymph node and blastic or lytic bone lesions (Gofrit et al., 2017, Sheikhbahaei
et al., 2017). In this study, we report an overexpression of SSTR2 in NEPC that could
potentially lead to overexpression of SSTR2 at the protein level and positivity in the uptake
of SSTR-radioligand. Interestingly, Morichetti et al. reported a strong specific staining for
SSTR2 in 20 cases of NEPC (Morichetti, Mazzucchelli et al., 2010). We speculate that
SSTR-radioligand might be a feasible tool to delineate PSMA-negative NEPC from the
normal tissue while PSMA-negative NEPC is not detectable by PSA measurements or by
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PSMA radiotracers. Future work to explore the role of SSTR2-targeted radionuclide
therapy for the detection and/or management of NEPC is of high priority.
Two possible scenarios for a patient with a suppressed PSMA radio-ligand uptake
after ARPI are illustrated on Figure 5-1. In an ideal condition, the PSMA radio-ligand
should be able to delineate AdPC tumor and all metastatic lesions (Figure 5-1A);
consequently, after therapy faint or a no PSMA radio-ligand uptake should be observed
since ARPI suppresses the malignancy (Figure 5-1B). However, as a second possible
scenario, we might face a high-grade NEPC with suppressed PSMA expression level
(Figure 5-1C). In this case, SSTR2 radio-ligand might be able to delineate NEPC tumor and
its metastatic lesions.
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Figure 5-1 A schematic of two possible scenarios for a patient with a suppressed PSMA radioligand uptake after ARPI.
(a) Delineation tumor and metastatic lesions by PSMA radio-ligand before ARPI. (b) Ideal
response to therapy and disappearance of the malignancy (High uptake of PSMA-radioligand and
no/low DOTATATE-radioligand uptake). (c) Development of NECP with a suppressed PSMA
expression level (No/low PSMA-radioligand uptake and high uptake for DOTATATEradioligand). Some elements of this figure were produced using Servier Medical Art image bank
(www.servier.com).

5.2

FDG-PET FOR NEPC SCREENING

The isoforms of GLUTs are structurally and functionally related proteins with different affinities
to glucose. They are expressed in different cells based on the metabolic necessity for glucose uptake
(Qian, Wang et al., 2014). The elevation of glycolysis in NEPC has been previously reported (Choi,
Ettinger et al., 2018, Li, Cohen et al., 2016a). Despite overall contribution of GLUT in glucose
metabolism, GLUT and HK family members could be associated with FDG uptake (Avril, 2004,
Yang et al., 2019). Like glucose, FDG is phosphorylated by HKs while their products, glucose-6phosphate and FDG-6-phosphate, could have different levels of inhibition on HKs depending on
their structure (McKerrecher & Waring, 2013). Figure 5-2 represents structural domains of the
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isoforms of human HK proteins (Roberts & Miyamoto, 2015). Glucokinase lacks the N-terminus
domain and cannot be inhibited by either glucose-6-phosphate or FDG-6-phosphate.

Figure 5-2 (A-D) Schematic of the structural domains of the isoforms of human HK proteins
including HK1, HK2, HK3 and HK4 or glucokinase (GCK).
HK1, 2 and 3 are around 100 kDa while glucokinase is about 50 kDa. N-terminus and C-terminus
domains have functional catalytic activity in HK2 while N-terminus domains in HK1 and 3 are
non-functional. Mitochondrial binding motif (MBF) at the N-terminal domain can be seen only in
HK2 and 1. *: non-functional domain. Adopted and modified with permission (Roberts &
Miyamoto, 2015).
GLUT11 is considered a high affinity glucose transporter and could be capable in elevation
of glucose uptake while it is overexpressed (Qian et al., 2014). McBrayer et al. (McBrayer, Cheng
et al., 2012) evaluated the association of GLUT11 expression and FDG uptake in multiple
myeloma. We have observed a significant elevation of GLUT11 expression in both NEPC and
NELPC. Similarly, GLUT7 and 8 have high affinity to glucose (Gonzalez-Menendez, Hevia et al.,
2018) and we observe their upregulation in samples with NEGS. Contrary to HK1-3, glucokinase
which is known as a glucose sensor in pancreatic beta-cells, is not inhibited by its product glucose6-phosphate but remains active while glucose is abundant (McKerrecher & Waring, 2013, Roberts
& Miyamoto, 2015). We can speculate that the apparent elevation of glucose uptake in NEPC or
NELPC could be due to elevation of the expression of the aforementioned high affinity of GLUTs
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(Figure 5-3). While our study provides functional support for this conclusion, it is also important
to remember the complexity associated with a focus on gene expression of this vast family of
glucose transport regulators. Avril’s commentary (Avril, 2004) elaborates on the complex number
of molecular, cellular, tissue and organ related variables regulating the resulting 18F-FDG signal,
all of which may provide inconsistencies between GLUT expression and the resulting 18F-FDG
signal.

Figure 5-3 The differential expression of GLUT and HK genes favor higher glucose uptake
in NEPC / NELPC in comparison with AdPC. Schematic shows the expression of high affinity
GLUT genes found to be elevated in NEPC and NELPC and it could result in increased
transport of glucose to the cytoplasm.
Drastic elevation of glucose sensor GCK in NEPC and NELPC is also demonstrated in this work.
Some elements of this figure were produced using Servier Medical Art image bank
(www.servier.com). GCK = Glucokinase
GLUT1 is a high affinity and basal glucose transporter expressed ubiquitously in human
tissues. In hormone sensitive PC, GLUT1 gene expression is positively correlated with androgen
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levels (Vaz, Marques et al., 2016). Our work implies that GLUT1 expression has limited prognostic
potential since it cannot estimate development or existence of low-AR phenotypes such as NEPC
or DNPC phenotype. GLUT12 has been recently introduced as a downstream target of AR and its
expression is tightly regulated by androgens (White, Tsouko et al., 2018). Our data demonstrated
the SLC2A12 suppression is also a highly associated with development of PSMA-low and NE-high
gene signature in mCRPC. This work shows GCK-enhanced expression and SLC2A12 suppression
at expression level correlate with the suppression in expression of PSMA, higher GS and shorter
time to biochemical recurrence in NELPC.
Hope et al. (Hope et al., 2019) represented the detection rate of 68Ga-PSMA-11 was estimated
0.94 for high- prostate-specific antigen (PSA) patients while this rate falls to 0.63 for low-PSA
patients. Parida at al. (Parida et al., 2018) reported a NEPC patient with a low PSMA-radioligand
uptake and a high FDG uptake. The identified low-PSA subclass of patients by Thang et al. (Thang
et al., 2018) has similar imaging outcomes. The identification of this PSMA-low or discordant
FDG-avid should be a high priory due to the apparent association with development of NEPC or
DNPC.

5.3

ZEBRAFISH PC MODEL
For pre-clinical studies, the use of FDG-imaging in mice xenografts can be limited by several

factors such as operating cost and short half-life of the radioactive substance and nonradioactive
glucose probes, which are of particular interest (Cheng et al., 2006). Also, the engraftment of
tumors in mice can be challenging to establish and are time-consuming. This work demonstrates
the feasibility of non-radioactive imaging of glucose uptake in PC xenografts using a zebrafish
model as a rapid and cost-effective model.
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Figure 5-4 Embryo zebrafish model for non-radioactive in vivo imaging of glucose uptake.
(A) An schematic of the required steps for measurement of glucose uptake in engrafted cells. (BC) The schematics and reprehensive images of zebrafish model of LNCaP.

5.4

FINAL CONCLUSIONS

We investigated whether the expression levels of glucose uptake-associated genes are correlated
with development of NEGS and/or suppression of the PSMA gene. Data mining approaches, cell
lines, mouse and zebrafish PDX models were used to demonstrate that GLUT and HK expression,
specially GCK and SCL2A12, are associated with NEGS, PSMA-suppression and higher glucose
uptake. This study supports the use of FDG-PET for imaging of low-PSMA PC tumors with NEGS.

156

5.5

REFERENCE

Avril N (2004) GLUT1 Expression in Tissue and 18F-FDG Uptake. J Nucl Med 45: 930-932
Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW (2017b) Influence of androgen
deprivation therapy on the uptake of PSMA-targeted agents: emerging opportunities and
challenges. Nucl Med Mol Imaging (2010) 51: 202-211
Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C (2015) Metastatic
poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68GaPSMA PET/CT. Clinical nuclear medicine 40: e163-166
Chang P-C, Wang T-Y, Chang Y-T, Chu C-Y, Lee C-L, Hsu H-W, Zhou T-A, Wu Z, Kim
RH, Desai SJ, Liu S, Kung H-J (2014) Autophagy Pathway Is Required for IL-6 Induced
Neuroendocrine Differentiation and Chemoresistance of Prostate Cancer LNCaP Cells. PLOS ONE
9: e88556
Cheng Z, Levi J, Xiong Z, Gheysens O, Keren S, Chen X, Gambhir SS (2006) Near-infrared
fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice.
Bioconjugate chemistry 17: 662-669
Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner
NE (2018) Targeting MCT 4 to reduce lactic acid secretion and glycolysis for treatment of
neuroendocrine prostate cancer. Cancer Med
Gofrit ON, Frank S, Meirovitz A, Nechushtan H, Orevi M (2017) PET/CT With 68Ga-DOTATATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant
Prostate Cancer. Clinical nuclear medicine 42: 1-6
Gonzalez-Menendez P, Hevia D, Mayo JC, Sainz RM (2018) The dark side of glucose
transporters in prostate cancer: Are they a new feature to characterize carcinomas? International
journal of cancer 142: 2414-2424
Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR (2019) Meta-analysis of
68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J
Nucl Med 60: 786-793
Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR,
Small EJ, Evans MJ (2017) 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor
Inhibition: First Human Experience. Journal of Nuclear Medicine 58: 81-84
Li W, Cohen A, Sun Y, Squires J, Braas D, Graeber TG, Du L, Li G, Li Z, Xu X, Chen X,
Huang J (2016a) The role of CD44 in glucose metabolism in prostatic small cell neuroendocrine
carcinoma. Mol Cancer Res 14: 344-353
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G (2009)
Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma
with distant metastasis. Pathol Oncol Res 15: 167-72
McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST, Shanmugam M (2012) Multiple
myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose
transporter-directed therapy. Blood 119: 4686-4697
McKerrecher D, Waring MJ (2013) Chapter One - Property-Based Design in the Optimisation
of Benzamide Glucokinase Activators: From Hit to Clinic. In Prog Med Chem, Lawton G, Witty
DR (eds) pp 1-43. Elsevier
Morichetti D, Mazzucchelli R, Santinelli A, Stramazzotti D, Lopez-Beltran A, Scarpelli M,
Bono A, Cheng L, Montironi R (2010) Immunohistochemical expression and localization of
somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation.
International journal of immunopathology and pharmacology 23: 511-522

157

Nouri M, Caradec J, Anne Lubik A, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen
M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang S-C, Cochrane D,
Cox M, Collins C, Gleave M, Erho N, Alshalafa M et al. (2017) Therapy-induced developmental
reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget 8
Parida GK, Tripathy S, Datta Gupta S, Singhal A, Kumar R, Bal C, Shamim SA (2018)
Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG
PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT. Clinical nuclear medicine
43: 248-249
Qian Y, Wang X, Chen X (2014) Inhibitors of glucose transport and glycolysis as novel anticancer
therapeutics. World J Transl Med 3: 37-57
Roberts DJ, Miyamoto S (2015) Hexokinase II integrates energy metabolism and cellular
protection: Akting on mitochondria and TORCing to autophagy. Cell death and differentiation 22:
364
Sang M, Hulsurkar M, Zhang X, Song H, Zheng D, Zhang Y, Li M, Xu J, Zhang S, Ittmann
M (2016) GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation
of prostate cancer cells. Oncotarget 7: 45171
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, Pienta KJ,
Allaf ME, Haberkorn U, Pomper MG, Gorin MA, Rowe SP (2017) Pearls and pitfalls in clinical
interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. European
journal of nuclear medicine and molecular imaging 44: 2117-2136
Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG,
Williams SG, Hicks RJ, Hofman MS (2018) Poor outcomes for patients with metastatic
castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA)
expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy. Eur Urol Oncol in
press
Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ, Pomper MG, Lotan TL,
Ross AE (2017a) Correlation of PSMA-Targeted (18)F-DCFPyL PET/CT Findings With
Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate
Cancer. Clinical genitourinary cancer 15: e65-e68
Usmani S, Ahmed N, Marafi F, Rasheed R, Amanguno HG, Al Kandari F (2017) Molecular
Imaging in Neuroendocrine Differentiation of Prostate Cancer: 68Ga-PSMA Versus 68Ga-DOTA
NOC PET-CT. Clinical nuclear medicine 42: 410-413
Vaz CV, Marques R, Alves MG, Oliveira PF, Cavaco JE, Maia CJ, Socorro S (2016)
Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by
modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes. J Cancer Res Clin
Oncol 142: 5-16
White MA, Tsouko E, Lin C, Rajapakshe K, Spencer JM, Wilkenfeld SR, Vakili SS, Pulliam
TL, Awad D, Nikolos F, Katreddy RR, Kaipparettu BA, Sreekumar A, Zhang X, Cheung E,
Coarfa C, Frigo DE (2018) GLUT12 promotes prostate cancer cell growth and is regulated by
androgens and CaMKK2 signaling. Endocr Relat Cancer 25: 453-469
Yang H, Zhong JT, Zhou SH, Han HM (2019) Roles of GLUT-1 and HK-II expression in the
biological behavior of head and neck cancer. Oncotarget 10: 3066-3083
Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF (2003) Receptor protein
tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine
differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 22: 6704-16
Zhang Y, Zheng D, Zhou T, Song H, Hulsurkar M, Su N, Liu Y, Wang Z, Shao L, Ittmann
M, Gleave M, Han H, Xu F, Liao W, Wang H, Li W (2018) Androgen deprivation promotes
neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate
cancers. Nat Commun 9: 4080-4080

158

APPENDICES
Appendix A
GB2-Cy3 Glucose Bioprobe Synthesis
Solvents were purchased from Caledon Laboratories (Caledon, Ontario), Sigma-Aldrich
(Oakville, Ontario), or VWR Canada (Mississauga, Ontario). Other chemicals were
purchased from Sigma-Aldrich, AK Scientific, Oakwood Chemicals, Alfa Aesar, or Acros
Chemicals and were used without further purification unless otherwise noted. Anhydrous
toluene, tetrahydrofuran (THF), diethyl ether, and N,N-dimethylformamide (DMF) were
obtained from an Innovative Technology (Newburyport, United States) solvent purification
system based on aluminum oxide columns. CH2Cl2, and acetonitrile were freshly distilled
from CaH2 prior to use. Purified water was obtained from a Millipore deionization system.
All heated reactions were conducted using oil baths on IKA RET Basic stir plates equipped
with a P1000 temperature probe. Thin layer chromatography was performed using EMD
aluminum-backed silica 60 F254-coated plates and visualized using either UV-light (254
nm), KMnO4, vanillin, Hanessian’s stain, or Dragendorff’s stain. Preparative TLC was
done using glass-backed silica plates (Silicycle) of either 250, 500, 1000, or 2000 μm
thickness depending on application. Column chromatography was carried out using
standard flash technique with silica (Silicycle Siliaflash-P60, 230−400 mesh) under
compressed air pressure. Standard workup procedure for all reactions undergoing an
aqueous wash involved back extraction of every aqueous phase, drying of the combined
organic phases with anhydrous magnesium sulfate, filtration either using vacuum and a
sintered-glass frit or through a glass-wool plug using gravity, and concentration under
reduced pressure on a rotary evaporator (Buchi or Synthware). 1H Nuclear magnetic
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resonance (NMR) spectra were obtained at 300 or 500 MHz, and 13C NMR spectra were
obtained at 75 or 125 MHz on Bruker instruments. NMR chemical shifts (δ) are reported
in ppm and are calibrated against residual solvent signals of CHCl3 (δ 7.26), DMSO-d5 (δ
2.50) or methanol-d3 (δ 3.31). HRMS analyses were conducted on a Waters XEVO G2-XS
TOF instrument with an ASAP probe in CI mode.
Compound (100): (2-bromoethyl)-D-glucoside

HO
HO

OH
O

OH

Br
O

To a solution of glucose (5 g, 27.75 mmol) in 2-bromoethanol (30 mL, 0.417 mol) was
added Dowex 50WX8-400 hydrogen form ion-exchange resin (5 g; the resin was washed
with MeOH before use) and the reaction mixture was refluxed at 70 °C for 16 h and the
reaction completion was monitored by TLC (2:1, ethyl acetate: hexanes). The reaction
mixture was filtered to remove the resin, poured into methanol (10 mL) and dried (MgSO4).
The resulting solution was filtered and concentrated under reduced pressure. After
purification of the glycosylated compound by silica gel flash column chromatography (1:1,
ethyl acetate: hexanes), the desired compound was obtained as a mixture of α and β
anomers (6.24 g. 78% yield). The analytical data were consistent with the literature values
(Lee et al., 2011).

Compound (101): (2-Bromoethyl)-2,3,4,6-tetra-O-benzoyl-α-D-glucoside
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BzO
BzO

OBz
O

Br

BzO
O

Compound 100 (1.89 g, 6.58 mmol) was dissolved in a mixture of pyridine (40 mL) and
4-DMAP (81 mg, 0.66 mmol) at 0 °C. Benzoyl chloride (6.1 mL, 53 mmol) was then added
dropwise and the resulting mixture was allowed to warm to room temperature with stirring
for 16 h. The mixture was quenched by the addition of methanol (10 mL) and subsequently
extracted with ethyl acetate (3 × 20 mL); the combined organic extracts were washed with
1 M HCl (2 × 10 mL), saturated sodium bicarbonate (1 × 10 mL), and brine (1 × 10 mL).
The organic layer was dried (MgSO4), filtered and the solvent removed under reduced
pressure. The resulting oil was purified using silica-gel chromatography (3:1 hexanes/ethyl
acetate) to give compound 101 (3.4 g, 74% yield). The analytical data were consistent with
the literature values (Lee et al., 2011).

Compound (102): [2-(N-Boc-piperazynoethyl)]-2,3,4,6-tetra-O-benzoyl-α-D-glucoside
BzO
BzO

OBz
O

NBoc
N

BzO
O

To a solution of Compound 101 (1 g, 1.42 mmol) in 15 mL anhydrous DMF was added
N-Boc-piperazine (529 mg, 2.84 mmol), potassium iodide (426 mg, 2.84 mmol) and Et3N
(593 μL, 4.26 mmol), and the resultant mixture was stirred at 80 °C for 10 h. After the
reaction was complete, as monitored by TLC, the solution was diluted with water (10 mL),
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extracted with ethyl acetate (3 × 20mL) and the combined organic layers washed with brine
(1 × 20 mL). The organic layer was dried (MgSO4) and concentrated under reduced
pressure. The desired product was purified by silica-gel chromatography (95:3:2, CHCl3:
EtOH: Et3N) to furnish a light yellow crystalline powder (680 mg, 59% yield). The
analytical data was consistent with the literature values (Lee et al., 2011).

Scheme S1. Overview of the synthesis of the conjugatable dye Cy3-OH.

Compound (103): 1,2,3,3-tetramethyl-3H-indolium iodide
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To a 0.3 M solution of 2,3,3-trimethylindolenine (5 mL,
31.15 mmol) in MeCN (104 mL), was added iodomethane (2.23
mL, 37.38 mmol) and the reaction was stirred at room
temperature for 16 h, resulting in a pale pink precipitate. The
precipitate was filtered and rinsed with Et2O (3 × 10 mL) to afford compound 103 (5.1 g,
54% yield). The analytical data were consistent with the literature.

Compound (104): (E)-1,3,3-trimethyl-2-(2-(N-phenylacetamido)vinyl)-3H-indolium
iodide
As per reference (Korbel et al., 2001): To 1,2,3,3tetramethyl-3H-indolium iodide, 103, (3 g, 9.96 mmol),
N,N′-diphenylformamidine (2.44 g, 12.45 mmol), and
potassium acetate (98 mg, 0.996 mmol) was added 22.5
mL acetic anhydride and the mixture was heated for 5 h at 120 °C. The reaction was then
allowed to cool to room temperature and the red precipitate was collected by filtration. The
precipitate was washed repeatedly with Et2O until the filtrate was colorless providing
compound 104 (2.7 g, 59%). Rf = 0.81 (DCM : MeOH = 4 : 1). The 1H NMR was consistent
with the literature: 1H-NMR (500 MHz, CDCl3, 23 °C) δ 9.19-9.16 (d, J = 14.2 Hz, 1H);
3.86 (s, 3H); 2.11 (s, 3H); 1.83 (s, 6H) ppm (Korbel et al., 2001).
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Compound (105): 1-(4-Carboxybutyl)-2,3,3-trimethyl-3H-indolium bromide
As per reference (Korbel et al., 2001): To 5bromovaleric acid (4.74 g, 26.17 mmol) was added
2,3,3-trimethylindolenine (4 mL, 24.92 mmol) and the
neat reaction was stirred for 20 h at 110 °C. The reaction completion was determined when
the solution had become a dark red solid and would no longer stir. The crude solid was
ground up with a pestle and mortar to create a fine powder. The powder was placed on top
of a filter paper in a Buchner funnel and was rinsed with boiling EtOAc (6 × 30 mL),
boiling acetone (2 × 30 mL), and boiling acetone (2 × 90 mL) to yield compound 105 (5.43
g, 64%) as an off-white, pink powder. Rf = 0.12 (DCM/MeOH = 3:1). The 1H NMR was
consistent with the literature: 1H NMR (500 MHz, CD3OD + 1 drop D2O, 23 °C) 7.90-7.87
(m, 1H); 7.78-7.75 (m, 1H); 7.67-7.63 (m, 2H); 4.56-4.52 (t, J = 7.7 Hz, 2H); 2.44-2.40 (t,
J = 7.0 Hz, 2H); 2.04-1.96 (m, 2H); 1.80-1.72 (m, 2H); 1.61 (s, 6H) ppm (Korbel et al.,
2001).

Compound (106): 1-[(4″-(1″-Carboxybutyl))]-1′,3,3,3′,3′-pentamethylindocarbocyanine iodide, “Cy3-OH,” (Korbel et al., 2001)
As per reference (Korbel et al., 2001): To a flamedried flask containing 104 (0.73 g, 1.59 mmol), 105
(0.54 g, 1.59 mmol), and potassium acetate (0.156 g,
1.905 mmol) was added anhydrous 1-butanol under a
nitrogen atmosphere (Korbel et al., 2001). The solution was stirred at 100 °C for 1.5 h. NaI
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(4.58 g, 30.53 mmol) was then added to the flask and the reaction was stirred at 100 °C for
a further 1 h. The reaction was cooled to room temperature and a precipitate formed
overnight. The precipitate was filtered using a Buchner funnel and then rinsed repeatedly
using Et2O until the filtrate was colorless. The precipitate was collected and dissolved in
DCM to give a dark purple solution. The crude mixture was purified by silica-gel flash
column chromatography using a gradient elution starting at 9:1 DCM/MeOH (v/v) to 4:1
DCM/MeOH (v/v) to give the title compound 106 (543 mg, 60% yield). Rf = 0.66 (4:1
DCM/MeOH). lmax 546 nm.27 The 1H NMR was consistent with the literature 1H NMR (500
MHz, CDCl3, 23 °C) δ 8.34-8.27 (dd, J = 14, 13 Hz, 1H); 7.35-7.29 (m, 4H); 7.22-7.16 (m,
2H); 7.11-7.07 (m, 2H); 6.78 (dd, J = 14 Hz, J = 14 Hz, 2H); 4.13 (bt, 2H); 3.71 (s, 3H);
2.47 (bt, 2H); 1.85 (m, 4H); 1.65 (s, 6H).
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Scheme S2. Synthetic strategy for the preparation of GB2-Cy3
Compound (107): Tert-butyl-4-(2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethyl)piperazine-1-carboxylate
As per reference (Park et al., 2007): To a
solution of 104 (66.4 mg, 0.0821 mmol) in
MeOH (3.3 mL) was added MeONa (~0.5 M in
MeOH, 1.22 mL, 0.611 mmol) and the reaction
completion was determined by TLC (100% MeOH). After the reaction was complete, the
mixture was neutralized with Dowex 50WX8-400 hydrogen form ion-exchange resin (1
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scoop the size of a pea), and then concentrated under reduced pressure. The residue was
dissolved in a minimal amount of MeOH and the methyl benzoate ester was removed using
a silica plug (25 mL SiO2) washed with three 25 mL portions of Et2O. Between each Et2O
portion, the filtrate was monitored by TLC to ensure only the methyl benzoate was being
eluted (Rf = 0.9 to 1.0, 100% Et2O). Unlike reference (Park et al., 2007), the compound
was isolated. The desired compound, 107, was then eluted using MeOH (25 mL) and the
solvent removed under reduced pressure (26.4 mg, 82% yield). The 1H NMR was
consistent with the expected spectrum (Park et al., 2007).

Compound (108): (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(2-(piperazin-1yl)ethoxy)tetrahydro-2H-pyran-3,4,5-triol (Park et al., 2007).
As per reference (Park et al., 2007): 1:1 Trifluoroacetic
acid (5.5 mL, excess) in DCM (5.5 mL) was added to
compound 107 (50 mg, 0.1274 mmol) for 1 h followed
by evaporation and purging with nitrogen. Unlike
reference (Park et al., 2007), the compound was isolated. The resulting residue was washed
with toluene (3 × 5 mL) and decanted to remove any residual TFA. Any residual toluene
was removed under reduced pressure to give compound 108 (18.6 mg, 50% yield). The 1H
NMR was consistent with the expected spectrum (Park et al., 2007).

Compound (109): GB2-Cy3
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As per reference (Lee et al., 2011) with
modifications:

Compound

108

(20

mg,

0.0684 mmol) in DMF (300 μL) was slightly
basified with DIPEA (20 μL) and Cy3-OH
(106) (30.3 mg, 0.0684 mmol) and EDC (7 mg,
0.046 mmol) added as a solution in DMF (50 μL). The reaction mixture was stirred at room
temperature for 2 h and the reaction was monitored by TLC. The resulting solution was
purified by prep high performance liquid chromatography (HPLC) and the elution protocol
is as listed: 1) 95% eluent A and 5% eluent B for 5 min, 2) linear gradient to 60% eluent A
(40% B) over 4 min, 3) linear gradient to 50% eluent A (50% B) over 10 min, 4) linear
gradient to 5% eluent A (95% B) over 10 min, 5) linear gradient to 0% eluent A (100% B)
over 5 min, 6) constant flow with 0% eluent A (100% B) for 10 min, and 7) linear gradient
to 95% eluent A (5% B) over 10 min for regeneration and washing of the column. Retention
time = 12 min, scanning for a lmax 546 nm to give GB2-Cy3 (109) (17 mg, 35% yield). The
1

H NMR was consistent with the literature: 1H NMR (500 MHz, CD3OD) δ 8.55 (t, J =

13.5 Hz, 1H), 7.54 (d, J = 7.5 Hz, 2H), 7.47–7.30 (m, 6H), 6.45 (dd, J = 13.4, 9.0 Hz, 2H),
4.20–4.17 (m, 2H), 4.08–4.05 (m, 1H), 3.83–3.80 (m, 3H), 3.67 (s, 3H) 3.63–3.42 (m,
12H), 2.57–2.54 (m, 2H), 1.97–1.79 (m, 6H), 1.78 (s, 6H), 1.77 (s, 6H) ppm (Lee et al.,
2011).
NMR spectrum of compound 101-106 are presented on Supplemental Figs. 16-22. HPLC
spectrum of GB2-Cy3 is illustrated onAppendix Figure 1 to Appendix Figure 8.
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1

Appendix Figure 1 H NMR spectrum of functionalized glucose (compound 100) with a
minimum of 85% α-anomer.
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Appendix Figure 2 1H NMR spectrum of protected functionalized glucose (compound 101).

Appendix Figure 3 1H NMR spectrum of piperazine-functionalized glucose (compound 102).
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Appendix Figure 4 1H NMR spectrum of indolium salt (compound 103).

Appendix Figure 5 1H NMR spectrum of acetamide-functionalized indolium salt (compound
104).
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Appendix Figure 6 1H NMR spectrum of carboxylate-functionalized indolium salt (compound
105).

1

Appendix Figure 7 H NMR spectrum of dye Cy3 (compound 106).
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Appendix Figure 8 HPLC spectrum of GB2-Cy3 (compound 106) at 546 nm. HPLC = High
performance liquid chromatography.
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